<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2682108-A2" country="EP" doc-number="2682108" kind="A2" date="20140108" family-id="48699690" file-reference-id="318320" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146585438" ucid="EP-2682108-A2"><document-id><country>EP</country><doc-number>2682108</doc-number><kind>A2</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-13175113-A" is-representative="YES"><document-id mxw-id="PAPP154847630" load-source="docdb" format="epo"><country>EP</country><doc-number>13175113</doc-number><kind>A</kind><date>20130704</date><lang>EN</lang></document-id><document-id mxw-id="PAPP179672020" load-source="docdb" format="original"><country>EP</country><doc-number>13175113.3</doc-number><date>20130704</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140552764" ucid="TR-201207842-A" load-source="docdb"><document-id format="epo"><country>TR</country><doc-number>201207842</doc-number><kind>A</kind><date>20120705</date></document-id></priority-claim><priority-claim mxw-id="PPC140557987" ucid="TR-201211213-A" load-source="docdb"><document-id format="epo"><country>TR</country><doc-number>201211213</doc-number><kind>A</kind><date>20121002</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL2049214478" load-source="docdb">A61K  31/40        20060101ALI20140228BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2049214479" load-source="docdb">A61K   9/00        20060101AFI20140228BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2049214480" load-source="docdb">A61K   9/14        20060101ALI20140228BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2049214481" load-source="docdb">A61K  31/439       20060101ALI20140228BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL2049214482" load-source="docdb">A61K  31/4704      20060101ALI20140228BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1913142717" load-source="docdb" scheme="CPC">A61K  47/10        20130101 LI20160728BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1913144235" load-source="docdb" scheme="CPC">A61K   9/0075      20130101 FI20160730BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1913145730" load-source="docdb" scheme="CPC">A61K  31/138       20130101 LI20160730BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1913148725" load-source="docdb" scheme="CPC">A61K  47/26        20130101 LI20160730BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036690342" load-source="docdb" scheme="CPC">A61K  47/12        20130101 LI20150723BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036690838" load-source="docdb" scheme="CPC">A61M2202/064       20130101 LA20150723BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036693049" load-source="docdb" scheme="CPC">A61K  45/06        20130101 LI20150723BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036693243" load-source="docdb" scheme="CPC">A61K  31/137       20130101 LI20150724BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036694502" load-source="docdb" scheme="CPC">A61K  31/439       20130101 LI20150724BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036694538" load-source="docdb" scheme="CPC">A61K  31/40        20130101 LI20150724BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036695575" load-source="docdb" scheme="CPC">A61K  31/27        20130101 LI20150723BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036697453" load-source="docdb" scheme="CPC">A61K  31/538       20130101 LI20150723BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036698233" load-source="docdb" scheme="CPC">A61M  15/0045      20130101 LI20150723BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036698456" load-source="docdb" scheme="CPC">A61K   9/145       20130101 LI20150724BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036698524" load-source="docdb" scheme="CPC">A61K  31/4704      20130101 LI20150724BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036698695" load-source="docdb" scheme="CPC">A61M  15/003       20130101 LI20150723BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2036701615" load-source="docdb" scheme="CPC">A61K  31/46        20130101 LI20150724BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989623668" load-source="docdb" scheme="CPC">A61K  31/56        20130101 LI20131118BHEP        </classification-cpc><classification-cpc mxw-id="PCL2094208071" load-source="docdb" scheme="CPC">A61K  31/167       20130101 LI20140708BHEP        </classification-cpc><classification-cpc mxw-id="PCL2094210821" load-source="docdb" scheme="CPC">A61K  31/24        20130101 LI20140708BHEP        </classification-cpc><classification-cpc mxw-id="PCL2094212364" load-source="docdb" scheme="CPC">A61K  31/573       20130101 LI20140708BHEP        </classification-cpc><classification-cpc mxw-id="PCL2094213417" load-source="docdb" scheme="CPC">A61K  31/44        20130101 LI20140708BHEP        </classification-cpc><classification-cpc mxw-id="PCL2094213714" load-source="docdb" scheme="CPC">A61K  31/165       20130101 LI20140708BHEP        </classification-cpc><classification-cpc mxw-id="PCL2094214459" load-source="docdb" scheme="CPC">A61K  31/58        20130101 LI20140708BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132360947" lang="DE" load-source="patent-office">Trockenpulverinhalatoren mit einem anderen Träger als Lactose und einer Ternärkomponente</invention-title><invention-title mxw-id="PT132360948" lang="EN" load-source="patent-office">Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component</invention-title><invention-title mxw-id="PT132360949" lang="FR" load-source="patent-office">Inhalateurs de poudre sèche comprenant un support autre que le lactose et un composant ternaire</invention-title><citations><patent-citations><patcit mxw-id="PCIT273845707" load-source="docdb" ucid="EP-1894568-A1"><document-id format="epo"><country>EP</country><doc-number>1894568</doc-number><kind>A1</kind><date>20080305</date></document-id><sources><source name="SEA" category="Y" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT273848114" load-source="docdb" ucid="EP-1944018-A1"><document-id format="epo"><country>EP</country><doc-number>1944018</doc-number><kind>A1</kind><date>20080716</date></document-id><sources><source name="SEA" category="Y" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT273842007" load-source="docdb" ucid="EP-2100599-A1"><document-id format="epo"><country>EP</country><doc-number>2100599</doc-number><kind>A1</kind><date>20090916</date></document-id><sources><source name="SEA" category="Y" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT273838710" load-source="docdb" ucid="EP-2191821-A1"><document-id format="epo"><country>EP</country><doc-number>2191821</doc-number><kind>A1</kind><date>20100602</date></document-id><sources><source name="SEA" category="Y" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT273845832" load-source="docdb" ucid="WO-2005097126-A1"><document-id format="epo"><country>WO</country><doc-number>2005097126</doc-number><kind>A1</kind><date>20051020</date></document-id><sources><source name="SEA" category="Y" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT273847531" load-source="docdb" ucid="WO-2008000482-A1"><document-id format="epo"><country>WO</country><doc-number>2008000482</doc-number><kind>A1</kind><date>20080103</date></document-id><sources><source name="SEA" category="Y" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT273840524" load-source="docdb" ucid="WO-2012106575-A1"><document-id format="epo"><country>WO</country><doc-number>2012106575</doc-number><kind>A1</kind><date>20120809</date></document-id><sources><source name="SEA" category="XP" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>None</text><sources><source mxw-id="PNPL45211475" load-source="docdb" name="APP"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR1110355692" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ARVEN ILAC SANAYI VE TICARET AS</last-name><address><country>TR</country></address></addressbook></applicant><applicant mxw-id="PPAR919526431" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ARVEN ILAC SANAYI VE TICARET A.S.</last-name></addressbook></applicant><applicant mxw-id="PPAR919006148" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Arven Ilac Sanayi Ve Ticaret A.S.</last-name><iid>101404204</iid><address><street>Balabandere Cad. Ilac Sanayi Yolu, No: 14 Istinye</street><city>Istanbul 34460</city><country>TR</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919543419" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CIFTER UEMIT</last-name><address><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR919534522" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CIFTER, UEMIT</last-name></addressbook></inventor><inventor mxw-id="PPAR919007707" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Cifter, Ümit</last-name><address><street>SANOVEL Ilac Sanayi ve Ticaret A.S. Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye</street><city>34460 Istanbul</city><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR919515631" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>TUERKYILMAZ ALI</last-name><address><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR919514544" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>TUERKYILMAZ, ALI</last-name></addressbook></inventor><inventor mxw-id="PPAR919013015" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>TÜRKYILMAZ, Ali</last-name><address><street>SANOVEL Ilac Sanayi ve Ticaret A.S. Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye</street><city>34460 Istanbul</city><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR919524129" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>MUTLU ONUR</last-name><address><country>TR</country></address></addressbook></inventor><inventor mxw-id="PPAR919522390" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>MUTLU, ONUR</last-name></addressbook></inventor><inventor mxw-id="PPAR919017262" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>MUTLU, ONUR</last-name><address><street>SANOVEL Ilac Sanayi ve Ticaret A.S. Balabandere Cad. Ilac Sanayi Yolu No: 14 Istinye</street><city>34460 Istanbul</city><country>TR</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919013408" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Sevinç, Erkan</last-name><iid>101067716</iid><address><street>Istanbul Patent &amp; Trademark Consultancy Ltd. Plaza 33, Buyukdere Cad. No: 33/16 Sisli</street><city>34381 Istanbul</city><country>TR</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549820140" load-source="docdb">AL</country><country mxw-id="DS549748910" load-source="docdb">AT</country><country mxw-id="DS549747392" load-source="docdb">BE</country><country mxw-id="DS549823274" load-source="docdb">BG</country><country mxw-id="DS549826189" load-source="docdb">CH</country><country mxw-id="DS549747397" load-source="docdb">CY</country><country mxw-id="DS549748911" load-source="docdb">CZ</country><country mxw-id="DS549820146" load-source="docdb">DE</country><country mxw-id="DS549747398" load-source="docdb">DK</country><country mxw-id="DS549747399" load-source="docdb">EE</country><country mxw-id="DS549825426" load-source="docdb">ES</country><country mxw-id="DS549823275" load-source="docdb">FI</country><country mxw-id="DS549826194" load-source="docdb">FR</country><country mxw-id="DS549820147" load-source="docdb">GB</country><country mxw-id="DS549747400" load-source="docdb">GR</country><country mxw-id="DS549820148" load-source="docdb">HR</country><country mxw-id="DS549748912" load-source="docdb">HU</country><country mxw-id="DS549825427" load-source="docdb">IE</country><country mxw-id="DS549747409" load-source="docdb">IS</country><country mxw-id="DS549823276" load-source="docdb">IT</country><country mxw-id="DS549747410" load-source="docdb">LI</country><country mxw-id="DS549823277" load-source="docdb">LT</country><country mxw-id="DS549750297" load-source="docdb">LU</country><country mxw-id="DS549823282" load-source="docdb">LV</country><country mxw-id="DS549823283" load-source="docdb">MC</country><country mxw-id="DS549750298" load-source="docdb">MK</country><country mxw-id="DS549750299" load-source="docdb">MT</country><country mxw-id="DS549825428" load-source="docdb">NL</country><country mxw-id="DS549910098" load-source="docdb">NO</country><country mxw-id="DS549825429" load-source="docdb">PL</country><country mxw-id="DS549750300" load-source="docdb">PT</country><country mxw-id="DS549826195" load-source="docdb">RO</country><country mxw-id="DS549750309" load-source="docdb">RS</country><country mxw-id="DS549825434" load-source="docdb">SE</country><country mxw-id="DS549748925" load-source="docdb">SI</country><country mxw-id="DS549910099" load-source="docdb">SK</country><country mxw-id="DS549910100" load-source="docdb">SM</country><country mxw-id="DS549823284" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128673610" lang="EN" load-source="patent-office"><p id="pa01" num="0001">This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases. More particulary, the invention relates to pharmaceutical composition for inhalation further comprising a ternary component. In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them.</p></abstract><abstract mxw-id="PA128737766" lang="EN" source="EPO" load-source="docdb"><p>This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose, and its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases. More particulary, the invention relates to pharmaceutical composition for inhalation further comprising a ternary component. In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them.</p></abstract><description mxw-id="PDES63959598" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>Field of the Invention</b></heading><p id="p0001" num="0001">This invention is a novel pharmaceutical composition for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder in admixture with a pharmaceutically acceptable carrier and its use in the treatment of respiratory condition selected from asthma, chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases. More particulary, the invention relates to pharmaceutical composition for inhalation further comprising a ternary component.</p><p id="p0002" num="0002">In addition, the present invention relates to novel pharmaceutical composition for inhalation based on combinations of long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them.</p><heading id="h0002"><b>Background of the Invention</b></heading><p id="p0003" num="0003">Amines are organic compounds and functional groups that contain basic nitrogen atom with alone pair. Amines are derivatives of ammonia, wherein one or more hydrogen atoms have been replaced by a substituent such as an alkyl or aryl group. Therefore drugs having amines can be selected from the group comprising aclidinium, glycopyrronium, daratropium, indacaterol, vilanterol, carmeterol, olodaterol or pharmaceutically acceptable salts, or esters thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0004" num="0004">Most dry powder inhaler (DPI) formulations rely on lactose as a carrier. However, lactose cannot be used for compounds that interact with the reducing sugar function of the lactose. Such drugs are the ones having amine groups, especially having primary or secondary amine.</p><p id="p0005" num="0005">Another disadvantage can be the Maillard reaction which results from a chemical reaction between an amine group and a reducing sugar. Water content (humidty) and temperature are found to influence the degradation.</p><p id="p0006" num="0006">Thus, there is a need in the art to look for alternative carriers, other than lactose, that still possess the positive aspects but overcome the above mentioned disadvantages of lactose. Other sugars may comprise but not limited to mannitol, glucose, trehalose,<!-- EPO <DP n="2"> --> cellobiose, sorbitol and maltitol as potential carriers. Nevertheless, these new carriers may be more sensitive to humidity and extreme temperature according to lactose.</p><p id="p0007" num="0007">Additionally, carriers are used as a flow aid and facilitate the dose of the active into the lungs. Therefore the properties of the particles of the carrier play an important role in the formulation of dry powder inhaler (DPI). Thus, carriers should be carefully selected, designed and controlled for the use in a dry powder inhalation formulation.</p><p id="p0008" num="0008">Accordingly, formulations of dry powder Inhalers (DPI) must fulfill a set of requirements, whereby in particular the following are to be considered:</p><heading id="h0003"><u>Content uniformity of the active drug:</u></heading><p id="p0009" num="0009">In a single dose system, each capsule or blister needs to contain the same amount of drug. In a multi dose system, the same amount of drug must be released every time it is administered, to guarantee that the patient receives the same dose each time. The presence of carrier, such as mannitol, promotes content uniformity in what is generally a low-dosage medication.</p><heading id="h0004"><u>flowability:</u></heading><p id="p0010" num="0010">The design of the device, the characteristics of the active and the filling platform to be used will determine the appropriate characteristics of the carrier that will be needed. The flow properties of the formulation will be important to ensure that the overall device functions in the correct way and provides consistent performance. The choice of carrier is essential in ensuring that the device works correctly and delivers the right amount of active to the patient. Therefore to use mannitol as a carrier in two different particle sizes (fine and coarse) is essential.</p><heading id="h0005"><u>dose consistency:</u></heading><p id="p0011" num="0011">DPI devices have to show a consistent dose uniformity in order to guarantee that all doses from the device contain the correct quantitiy of the active. Regardless of a patient's inhalation ability, it is essential that the dose released by the DPI device is exactly the same every time. Therefore, using mannitol as a carrier with the right properties in the formulation assists dose-consistent delivery.</p><p id="p0012" num="0012">Accordingly, in order to penetrate into the deep lungs the active particles will have a particle size less than 10 microns and often lower than 4 microns. These small drug particles will have a tendency to agglomerate. By using the appropriate carrier (such as<!-- EPO <DP n="3"> --> mannitol) this drug to drug agglomeration can be prevented. Furthermore, the carrier (such as mannitol) will help to control the flowability, the drug release from the device and helps to ensure the correct and consistent dosage of the active that reaches the lungs.</p><p id="p0013" num="0013">Additionally, the formulation should be a homogeneous mixture where the drug particles adhere to the carrier. The adhesion should not be too strong as the drug will not be able to release from the carrier particle during inhalation. Furthermore, a low dose of powder should be filled into the device and the drug should always be released in the same way. One of the main important parameters for the formulation is the particle size of the carrier. Therefore, it is found that using the right ratio of the fine (small) and coarse (large) particles of the selected carrier in the present formulations of the invention is essential.</p><p id="p0014" num="0014">To fulfill all these requirements the formulations of DPIs needs to be adapted in particular by a careful selection of the carriers used. In order to meet these requirements, the inhalable, fine or microfine particles of active compounds are mixed with carriers. By means of the mixing process, the particle size of the carrier can also be changed such that a certain proportion is inhalable. The particle size of the carrier employed depends on the requirements and specifications of the powder inhaler which is intended for the administration of the formulation. It is true for these mixtures that during all required processing, transport, storage and dosage operations no segregation must take place, i.e. the active compound particles must not detach from their carrier particles. During dispersion in the inhaler, induced by the respiratory flow of the patient, the active compound particles, however, must be detached as effectively as possible, i.e. as quantitatively as possible, in order to be inhaled.</p><p id="p0015" num="0015">In prior art, there are several compounds used for the treatment of asthma but all these compounds include lactose as a carrier. None of them comprise mannitol, glucose, trehalose, cellobiose, sorbitol or maltitol as potential carriers may be because of their sensitivity to humidty and extreme temperature. This problem is also solved by using additional ternary components.</p><p id="p0016" num="0016">Ternary compounds can be magnesium stearate, stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol and sodium benzoate, could turn out to be suitable depending on the type of carrier and drug used. Especially the preffered one is magnesium stearate.<!-- EPO <DP n="4"> --></p><p id="p0017" num="0017">In prior art there are several examples of magnesium stearate use in inhalation formulations and mostly they suggest to coat the carrier with magnesium stearate or additionaly to use it with other additives. Although the respirable fraction increased when magnesium stearate was added, the known amount (min. 1.5% up to 5%) is too much and reduces the mechanical stability of the mixture before use. Furthermore, magnesium stearate is poorly water soluble, its presence in such amount may rise some concerns as to a potential irritation or toxicity of this excipient, part of which can be inhaled by the patient together with the active ingredient. According to prior art, these disadvantages can be solved by adding other additives such as silicon dioxide (aerosil), amino acids (leucine, lysine, valine, methionine or phenylalanine). Mostly L-leucine is preffered. As it is known that inhalable powders are so sensitive such that they have to be used in min. amounts and no other further additives may preferred because of their concern to toxicity.</p><p id="p0018" num="0018">Finally we have found that the introduction of magnesium stearate in such a small amount is safe and does not produce any toxicologically relevant effect after repeated administration.</p><p id="p0019" num="0019">Thus, there is still a need for the dry powder inhalation formulations comprising carriers other than lactose that are able to overcome the problems mentioned above and the problems related with interaction of carrier between the drugs having amine and furthermore the problems related to pulmonary administration of drugs and additionaly able to overcome the stability problems with the use a ternary compound. This invention also proposes the possibility to obtain different compositions and composition of combinations for pulmonary administration having satisfactory properties in terms of increasing drug deposition or accelerating drug release rate in a safe and effective way.</p><heading id="h0006">The Detailed Description of the <b>Invention</b></heading><p id="p0020" num="0020">This invention relates to novel pharmaceutical compositions for inhalation comprising separately, sequentially or together, drugs having amine in the form of dry powder in admixture with a pharmaceutically acceptable carrier, other than lactose which doesn't interact with the drugs especially having an amine group and further comprising a ternary component. The present invention further relates its use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease (COPD) and other obstructive airways diseases.<!-- EPO <DP n="5"> --></p><p id="p0021" num="0021">Accordingly, the main object of the present invention is to provide pharmaceutical compositions for inhalation which is stable throughout the shelflife, in other words, which prevents any chemical reaction between an amine group and reducing sugar which may cause degredation of the active and furthermore resistant to humidty and extreme temperature which may occur during the manufacturing process.</p><p id="p0022" num="0022">Ternary compounds which are suitable for this invention can be magnesium stearate, stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol and sodium benzoate or their mixtures, could turn out to be suitable depending on the type of carrier and drug used. Especially the preffered one is magnesium stearate. The preferred magnesium stearate can be in crystalline or amorphous form. Therefore, magnesium stearate is used to protect the drug, from moisture for inhalation use for stability purposes.</p><p id="p0023" num="0023">It has surprisingly been found that magnesium stearate is able to minimize the influence of penetrating moisture during the storage of the inhalation powder and stabilize the dry powder formulation. Thus, the quality of the pharmaceutical formulation remains considerably better than conventional formulations which are free of magnesium stearate even on storage under extreme conditions of temperature and humidity.</p><p id="p0024" num="0024">In addition to general moisture protection, it is found that magnesium stearate also stabilizes the carrier materials and active compounds by suppressing or slowing down undesirable morphological phase transitions.</p><p id="p0025" num="0025">It has also been found that magnesium stearate is suitable for improving the moisture resistance of any desired dry powder formulations.</p><p id="p0026" num="0026">Finally we have found that the introduction of magnesium stearate in such a small amount is safe and does not produce any toxicologically relevant effect after repeated administration.</p><p id="p0027" num="0027">Therefore, the amount of magnesium stearate can be, 0.05 to 2.0% by weight, in particular 0.1 to 1.0% by weight, more particularly it is 0.15 to 0.5% by weight, based on the total formulation.</p><p id="p0028" num="0028">The particle size may also important and therefore the preffered particle size of magnesium stearate is d10: 0.25 - 2.5, d50: 3.0 - 7.0, d90: 7.0 - 20.0.<!-- EPO <DP n="6"> --></p><p id="p0029" num="0029">The use according to the invention of magnesium stearate is furthermore especially advantageous for use in multidose dry powder inhalers which contain a powder reservoir from which the individual doses are withdrawn by means of a dosage mechanism. The use of magnesium stearate, however, is also suitable for improving the resistance to moisture of predosed units, which can be present, for example, in the form of capsules.</p><p id="p0030" num="0030">Another main object of the present invention is to provide pharmaceutical compositions for inhalation having an adequate content uniformity of the active in order to guarantee that the patient receives the same dose each time even in low-dosage formulations.</p><p id="p0031" num="0031">Another object of the present invention is to obtain the dose consistency of the active in order to guarantee that all doses from the device contain the correct quantitiy of the active. Using the carrier with the right properties and the right ratio in the formulation asissts dose-consistent delivery. According to this preffered embodiment, the weight ratio of the fine carrier particles to coarse carrier carrier particles, is between 0.01 - 0.25 by weight, preferably it is between 0.05 - 0.20 by weight.</p><p id="p0032" num="0032">According to a further embodiment of the invention, the fine carrier particles of the said pharmaceutically acceptable carrier have a particle diameter of d<sub>10</sub> between 1.0 - 4.0 µm, d<sub>50</sub> between 4.0 - 7.0 µm and d<sub>90</sub> between 7.0 - 15.0 µm. The coarse carrier particles of the said pharmaceutically acceptable carrier have a particle diameter of d<sub>10</sub> between 10.0 - 50.0 µm, d<sub>50</sub> between 50.0 - 75.0 µm and d<sub>90</sub> between 75.0 - 250.0 µm.</p><p id="p0033" num="0033">The coarse carrier particles are used to prevent (re)agglomeration of the fine particles of active. To provide this effect, carrier with a particle size of approximately ten times that of the active is used. Generally, a monolayer of the active particles is formed on the larger carrier particles. Since the active and carrier will have to be separated during inhalation, the shape and the surface roughness of the carrier particles is of significant importance. Carrier particles with a smooth surface will separate from the active more easily than highly porous particles of equal size.</p><p id="p0034" num="0034">The fine carrier particles are used to help the active to reach the lungs in a safer way and higher doses. Because the surface energy is normally not equally spread over the carrier particle, the active will tend to concentrate on higher energy sites. This can make separation of the active from the carrier following pulmonary delivery more difficult, especially for low dose formulations. The presence of fine carrier paticles, smaller than 10.0 micron or 5.0 micron, will help to prevent this, as the high energy sites will be<!-- EPO <DP n="7"> --> occupied by the fine carrier particles and the active will tend to attach to the low energy sites. It is found that lung deposition will increase with an increasing fraction of fine carrier particles. Accordingly a reduction in particle size (having finer particles) increases the fluidization energy and this enhances the increase of the amount of drug particles that will get into the lung.</p><p id="p0035" num="0035">The drug particles will then adhere to the lower adhesion sites and will be easier released during inhalation. With the addition of fines also the surface area increases significantly and the payload will be reduced. When the fine carrier particles are slightly coarser then the drug particles it could eliminate the friction forces between drug and carrier/mannitol in the mixing process.</p><p id="p0036" num="0036">Another object of the present invention is to obtain good flowability of the formulations to ensure that the right amount of the active is delivered by the devices for DPIs. In other words, in order to guarantee consistent production of the formulations, mechanical filling of the powder inhaler, correct dosage and release by the powder inhaler the present invention provides free-flowing formulations by selecting the right carrier.</p><p id="p0037" num="0037">Another object of the present invention is to prevent agglomeration by using appropriate carrier, other than lactose. Active particles have fine or sometimes microfine particles in order to penetrate into the deep lungs. Thus, these small drug particles will have a tendency to agglomerate.</p><p id="p0038" num="0038">In a preferred embodiment according to the present invention, the pharmaceutically acceptable carrier, other than lactose, is selected from the group comprising mannitol, glucose, trehalose, cellobiose, sorbitol, maltitol or a combination of two or more of them.</p><p id="p0039" num="0039">As a further embodiment, the carrier may be a combination of mannitol and glucose, or mannitol and trehalose, or mannitol and sorbitol, or mannitol and cellobiose, or mannitol and maltitol.</p><p id="p0040" num="0040">In a more preffered embodiment, the invention suggests to use mannitol as a carrier, more specifically to use spray-dried mannitol to achieve the best results.</p><p id="p0041" num="0041">In an ideal drug-carrier system, the adhesion of the active to the carriers is strong enough to prevent demixing during filling, handling and storage, but not so strong, since the active and carrier will have to be separated during inahalation. Therefore the shape and<!-- EPO <DP n="8"> --> the surface roughness of the carrier particles is of significant importance. It is found that spray-dried mannitol particles will separate from the active more easily than highly porous particles of equal size. Because spray dried mannitol produces more spherical particles and a smooth surface. Such particles are characterized by a lower area of contact and a smaller, more homogeneous particle size distribution that result in a higher respirable fraction than mechanically micronized carriers. One of the advantages for using spray-dried mannitol is to achieve particle diameters of several micrometers with a narrow particle size distribution. This ensures, assuming an appropriate diameter, a maximum deposition of the embedded drug in the tracheo-bronchial and deep alveoli regions at normal inhalation rates. Moreover, spray-dried mannitol exhibited a narrow particle size distribution which means the ratio between the median particle size (d<sub>50</sub>) and d<sub>90</sub> which is equal to or greater than 0.40. Preferably, the ratio between the median particle size and d d<sub>90</sub> is between 0.45 and 0.50, more preferably it is 0.50 and 0.70.</p><p id="p0042" num="0042">Additionaly, this narrow particle size distribution also applies to mannitol in the compositions of the present invention which is equal to or greater than 0.40. Preferably, the ratio of narrow particle size distribution is between 0.45 and 0.50, more preferably it is 0.50 and 0.70.</p><p id="p0043" num="0043">According to a preferred embodiment of the present invention, the average particle diameter (d<sub>50</sub>) of the drugs having amine is between 1.5 - 2.5 µm, and the amine is primary amine and/or secondary amine.</p><p id="p0044" num="0044">According to a preferred embodiment of the present invention, the drug having amine is aclidinium or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture. Preferably it can be aclidinium bromide.</p><p id="p0045" num="0045">According to a preferred embodiment of the present invention, the drug having amine is glycopyrronium or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture. Preferably it can be glycopyrronium bromide or glycopyrronium acetate.</p><p id="p0046" num="0046">According to a preferred embodiment of the present invention, the drug having amine is darotropium or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture. Preferably it can be darotropium bromide.<!-- EPO <DP n="9"> --></p><p id="p0047" num="0047">According to a preferred embodiment of the present invention, the drug having amine is indacaterol or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture. Preferably it can be indacaterol maleate.</p><p id="p0048" num="0048">According to a preferred embodiment of the present invention, the drug having amine is vilanterol or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture. Preferably it can be vilanterol trifenatate.</p><p id="p0049" num="0049">According to a preferred embodiment of the present invention, the drug having amine is carmoterol or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture. Preferably it can be carmoterol hydrochloride.</p><p id="p0050" num="0050">According to a preferred embodiment of the present invention, the drug having amine is olodaterol or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture. Preferably it can be olodaterol hydrochloride.</p><p id="p0051" num="0051">Asthma, chronic obstructive pulmonary disease and other related disorders have been known to be treated with beta-2 adrenergic receptor agonists as they provide a bronchodilator effect to the patients, resulting in relief from the symptoms of breathlessness. Beta-2 adrenergic receptor agonists can be short acting for immediate relief, or long acting for long-term prevention, of asthma symptoms. Long actings are long acting beta agonists (LABA) whose effect lasts for 12 hours or more. In a preferred embodiment, LABAs are selected from the group comprising salmeterol, formoterol, arformoterol, indacaterol, olodaterol, vilanterol, carmoterol, bambuterol or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture or a combination of two or more of them. Preferably LABAs can be salmeterol xinofoate, arformoterol tartarate, indacaterol tartarate, olodaterol hydrochloride, vilanterol trifenatate, carmoterol hydrochloride, bambuterol hydrochloride, formoterol fumarate or a combination of two or more of them.</p><p id="p0052" num="0052">Short actings are short acting beta-2 agonists (SABA). They are bronchodilators. They relax the muscles lining the airways that carry air to the lungs within 5 minutes, increasing airflow and making it easier to breathe. They relieve asthma symptoms for 3 to 6 hours. They do not control the inflammation. In a preferred embodiment, SABAs are selected from the group comprising salbutamol, levosalbutamol, terbutaline, pirbuterol, procaterol, fenoterol, biltolterol, ritodrine, metaproterenol or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture or a combination of<!-- EPO <DP n="10"> --> two or more of them. Preferably SABAs can be salbutamol sulphate, salbutamol hemisulphate, levosalbutamol sulphate, terbutaline sulfate, pirbuterol hydrochloride, pirbuterol acetate, procaterol hydrochloride, fenoterol hydrobromide, bitolterol mesylate, ritodrine hydrochloride, metaproterenol sulfate or a combination of two or more of them.</p><p id="p0053" num="0053">Whilst it is also known that, beta-2 agonists provide symptomatic relief of bronchoconstriction in patients, another component of asthma, i. e. inflammation, often requires separate treatment. According to this, involves treatment with a steroid. Treatment with an inhaled corticosteroid is considered one of the most potent and effective therapies currently available for persistent asthma. In a preffered embodiment, inhaled corticosteroids are selected from the group comprising fluticasone, ciclesonide, budesonide, mometasone, beclomethasone, triamcinolone, flunisolide, dexamethasone or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture or a combination of two or more of them. Preferably, the corticosteroids can be fluticasone propionate, fluticasone furoate, ciclesonide, budesonide, mometasone furoate, beclomethasone dipropionate, triamcinolone acetonide, flunisolide acetate, dexamethasone sodium phosphate or a combination of two or more of them.</p><p id="p0054" num="0054">Bronchoconstriction and inflammation are also associated with bronchial plugging with secretions, which may be treated with long acting muscarinic antagonists (LAMA). In a preffered embodiment LAMAs are selected from the group comprising tiotropium, glycopyrronium, ipratropium, aclidinium, oxitropium or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture or a combination of two or more of them. Preferably the LAMAs can be tiotropium bromide, glycopyrronium bromide, glycopyrronium acetate, ipratropium bromide, aclidinium bromide, oxitropium bromide or a combination of two or more of them.</p><p id="p0055" num="0055">According to this preferred embodiment of the present invention, the said pharmaceutical compositions may further comprise one or more additional active agents selected from long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, inhaled corticosteroids or a combination of two or more of them.</p><p id="p0056" num="0056">To assist better patient compliance, combination products are still needed. It would be highly desirable, however, to provide a combination therapy suitable to reduce bronchial inflammation, bronchial constriction and bronchial secretions in a single product or dosage form. It would also be desirable to provide such a combination product or<!-- EPO <DP n="11"> --> composition in a form whereby the correct dosage of the various components is easily and safely administered.</p><p id="p0057" num="0057">Therefore, in a preffered embodiment of the invention, the pharmaceutical compositions comprise the drugs having amine and long acting muscarinic antagonists, or comprise the drugs having amine and long acting beta agonists, or comprise the drugs having amine and short acting beta-2 agonists, or comprise the drugs having amine and inhaled corticosteroids.</p><p id="p0058" num="0058">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of aclidinium and tiotropium, aclidinium and glycopyrronium, aclidinum and ipratropium, aclidinum and oxitropium, glycopyrronium and tiotropium, glycopyrronium and ipratropium, glycopyrronium and oxitropium, darotropium and tiotropium, darotropium and glycopyrronium, darotropium and ipratropium, darotropium and aclidinium, darotropium and oxitropium, indacaterol and tiotropium, indacaterol and glycopyrronium, indacaterol and ipratropium, indacaterol and aclidinium, indacaterol and oxitropium, vilanterol and tiotropium, vilanterol and glycopyrronium, vilanterol and ipratropium, vilanterol and aclidinium, vilanterol and oxitropium, carmoterol and tiotropium, carmoterol and glycopyrronium, carmoterol and ipratropium, carmoterol and aclidinium, carmoterol and oxitropium, olodaterol and tiotropium, olodaterol and ipratropium, olodaterol and glycopyrronium, olodaterol and aclidinium, olodaterol and oxitropium wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture. According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of aclidinium and salmeterol, aclidinum and formoterol, aclidinium and arformoterol, aclidinium and indacaterol, aclidinium and olodaterol, aclidinium and vilanterol, aclidinium and carmoterol, aclidinium and bambuterol, glycopyrronium and salmeterol, glycopyrronium and formoterol, glycopyrronium and arformoterol, glycopyrronium and indacaterol, glycopyrronium and olodaterol, glycopyrronium and vilanterol, glycopyrronium and carmoterol, glycopyrronium and bambuterol, darotropium and salmeterol, darotropium and formoterol, darotropium and arformoterol, darotropium and indacaterol, darotropium and olodaterol, darotropium and vilanterol, darotropium and carmoterol, darotropium and bambuterol, indacaterol and salmeterol, indacaterol and formoterol, indacaterol and arformoterol, indacaterol and olodaterol, indacaterol and vilanterol, indacaterol and carmoterol, indacaterol and<!-- EPO <DP n="12"> --> bambuterol, vilanterol and salmeterol, vilanterol and formoterol, vilanterol and arformoterol, vilanterol and olodaterol, vilanterol and carmoterol, vilanterol and bambuterol, carmoterol and salmeterol, carmoterol and formoterol, carmoterol and arformoterol, carmoterol and olodaterol, carmoterol and bambuterol, olodaterol and salmeterol, olodaterol and formoterol, olodaterol and arformoterol, olodaterol and bambuterol wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0059" num="0059">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of aclidinium and salbutamol, aclidinium and levosalbutamol, aclidinium and terbutaline, aclidinium and pirbuterol, aclidinium and procaterol, aclidinium and fenoterol, aclidinium and bitolterol, aclidinium and ritodrine, aclidinium and metaproterenol, glycopyrronium and salbutamol, glycopyrronium and levosalbutamol, glycopyrronium and terbutaline, glycopyrronium and pirbuterol, glycopyrronium and procaterol, glycopyrronium and fenoterol, glycopyrronium and bitolterol, glycopyrronium and ritodrine, glycopyrronium and metaproterenol, darotropium and salbutamol, darotropium and levosalbutamol, darotropium and terbutaline, darotropium and pirbuterol, darotropium and procaterol, darotropium and fenoterol, darotropium and bitolterol, darotropium and ritodrine, darotropium and metaproterenol, indacaterol and salbutamol, indacaterol and levosalbutamol, indacaterol and terbutaline, indacaterol and pirbuterol, indacaterol and procaterol, indacaterol and fenoterol, indacaterol and bitolterol, indacaterol and ritodrine, indacaterol and metaproterenol, vilanterol and salbutamol, vilanterol and levosalbutamol, vilanterol and terbutaline, vilanterol and pirbuterol, vilanterol and procaterol, vilanterol and fenoterol, vilanterol and bitolterol, vilanterol and ritodrine, vilanterol and metaproterenol, carmoterol and salbutamol, carmoterol and levosalbutamol, carmoterol and terbutaline, carmoterol and pirbuterol, carmoterol and procaterol, carmoterol and fenoterol, carmoterol and bitolterol, carmoterol and ritodrine, carmoterol and metaproterenol, olodaterol and salbutamol, olodaterol and levosalbutamol, olodaterol and terbutaline, olodaterol and pirbuterol, olodaterol and procaterol, olodaterol and fenoterol, olodaterol and bitolterol, olodaterol and ritodrine, olodaterol and metaproterenol wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0060" num="0060">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or<!-- EPO <DP n="13"> --> together in effective amounts of aclidinium and fluticasone, aclidinium and ciclesonide, aclidinium and budesonide, aclidinium and mometasone, aclidinium and beclomethasone, aclidinium and triamcinolone, aclidinium and flunisolide, aclidinium and dexamethasone, glycopyrronium and fluticasone, glycopyrronium and ciclesonide, glycopyrronium and budesonide, glycopyrronium and mometasone, glycopyrronium and beclomethasone, glycopyrronium and triamcinolone, glycopyrronium and flunisolide, glycopyrronium and dexamethasone, darotropium and fluticasone, darotropium and ciclesinide, darotropium and budesonide, darotropium and mometasone, darotropium and beclomethasone, darotropium and triamcinolone, darotropium and flunisolide, darotropium and dexamethasone, indacaterol and fluticasone, indacaterol and ciclesonide, indacaterol and budesonide, indacaterol and mometasone, indacaterol and beclomethasone, indacaterol and triamcinolone, indacaterol and flunisolide, indacaterol and dexamethasone, vilanterol and fluticasone, vilanterol and ciclesonide, vilanterol and budesonide, vilanterol and mometasone, vilanterol and beclomethasone, vilanterol and triamcinolone, vilanterol and flunisolide, vilanterol and dexamethasone, carmoterol and fluticasone, carmoterol and ciclesonide, carmoterol and budesonide, carmoterol and mometasone, carmoterol and beclomethasone, carmoterol and triamcinolone, carmoterol and flunisolide, carmoterol and dexamethasone, olodaterol and fluticasone, olodaterol and ciclesonide, olodaterol and budesonide, olodaterol and mometasone, olodaterol and beclamethasone, olodaterol and triamcinolone, olodaterol and flunisolide, olodaterol and dexamethasone wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0061" num="0061">We have also found that certain therapeutic three-in-one combinations further comprising specific, LABAs, SABAs, LAMAs and/or inhaled corticosteroids surprisingly provide an enhanced, synergistic, effect in terms of treatment of bronchoconstriction, inflammation and mucous secretions of airways. Also the three-in-one combination therapy as provided by the present invention is an extremely patient-friendly combination, which results in maximum patient compliance and better control of asthma and chronic obstructive pulmonary disease than the known combinations or single therapies.</p><p id="p0062" num="0062">It will also be appreciated from the above that the respective therapeutic agents of the combined preparations can be administered simultaneously, either in the same or different pharmaceutical formulations, or separately or sequentially. If there is separate or sequential administration, it will also be appreciated that the subsequently administered therapeutic agents should be administered to a patient within a time scale so as to<!-- EPO <DP n="14"> --> achieve, or more particularly optimise, the above referred to advantageous synergistic therapeutic effect of a combined preparation as present in a pharmaceutical product according to the present invention.</p><p id="p0063" num="0063">Therefore, in a further embodiment, the pharmaceutical compositions of the invention comprise the drugs having amine, long acting muscarinic antagonists and long acting beta agonists, or comprise the drugs having amine, long acting muscarinic antagonists and short acting beta-2 agonists, or comprise the drugs having amine, long acting muscarinic antagonists and inhaled corticosteorids, or comprise the drugs having amine, long acting beta angonists and short acting beta-2 agonists, or comprise the drugs having amine, long acting beta angonists and inhaled corticosteorids, or comprise the drugs having amine, short acting beta-2 agonists and inhaled corticosteorids.</p><p id="p0064" num="0064">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of;
<ul><li>i. Aclidinum, tiotropium and salmeterol</li><li>ii. Aclidinum, tiotropium and formoterol</li><li>iii. Aclidinum, tiotropium and arformoterol</li><li>iv. Aclidinum, tiotropium and indacaterol</li><li>v. Aclidinum, tiotropium and olodaterol</li><li>vi. Aclidinum, tiotropium and vilanterol</li><li>vii. Aclidinum, tiotropium and carmoterol</li><li>viii. Aclidinum, tiotropium and bambuterol</li><li>ix. Aclidinum, glycopyrronium and salmeterol</li><li>x. Aclidinum, glycopyrronium and formoterol</li><li>xi. Aclidinum, glycopyrronium and arformoterol</li><li>xii. Aclidinum, glycopyrronium and indacaterol</li><li>xiii. Aclidinum, glycopyrronium and olodaterol</li><li>xiv. Aclidinum, glycopyrronium and vilanterol</li><li>xv. Aclidinum, glycopyrronium and carmoterol</li><li>xvi. Aclidinum, glycopyrronium and bambuterol</li><li>xvii. Aclidinum, oxitropium and salmeterol</li><li>xviii. Aclidinum, oxitropium and formoterol</li><li>xix. Aclidinum, oxitropium and arformoterol</li><li>xx. Aclidinum, oxitropium and indacaterol</li><li>xxi. Aclidinum, oxitropium and olodaterol<!-- EPO <DP n="15"> --></li><li>xxii. Aclidinum, oxitropium and vilanterol</li><li>xxiii. Aclidinum, oxitropium and carmoterol</li><li>xxiv. Aclidinum, oxitropium and bambuterol</li><li>xxv. Glycopyrronium, tiotropium and salmeterol</li><li>xxvi. Glycopyrronium, tiotropium and formoterol</li><li>xxvii. Glycopyrronium, tiotropium and arformoterol</li><li>xxviii. Glycopyrronium, tiotropium and indacaterol</li><li>xxix. Glycopyrronium, tiotropium and olodaterol</li><li>xxx. Glycopyrronium, tiotropium and vilanterol</li><li>xxxi. Glycopyrronium, tiotropium and carmoterol</li><li>xxxii. Glycopyrronium, tiotropium and bambuterol</li><li>xxxiii. Glycopyrronium, oxitropium and salmeterol</li><li>xxxiv. Glycopyrronium, oxitropium and formoterol</li><li>xxxv. Glycopyrronium, oxitropium and arformoterol</li><li>xxxvi. Glycopyrronium, oxitropium and indacaterol</li><li>xxxvii. Glycopyrronium, oxitropium and olodaterol</li><li>xxxviii. Glycopyrronium, oxitropium and vilanterol</li><li>xxxix. Glycopyrronium, oxitropium and carmoterol</li><li>xl. Glycopyrronium, oxitropium and bambuterol</li><li>xli. Daratropium, tiotropium and salmeterol</li><li>xlii. Daratropium, tiotropium and formoterol</li><li>xliii. Daratropium, tiotropium and arformoterol</li><li>xliv. Daratropium, tiotropium and indacaterol</li><li>xlv. Daratropium, tiotropium and olodaterol</li><li>xlvi. Daratropium, tiotropium and vilanterol</li><li>xlvii. Daratropium, tiotropium and carmoterol</li><li>xlviii. Daratropium, tiotropium and bambuterol</li><li>xlix. Daratropium, gycopyrronium and salmeterol</li><li>l. Daratropium, gycopyrronium and formoterol</li><li>li. Daratropium, gycopyrronium and arformoterol</li><li>lii. Daratropium, gycopyrronium and indacaterol</li><li>liii. Daratropium, gycopyrronium and olodaterol</li><li>liv. Daratropium, gycopyrronium and vilanterol</li><li>lv. Daratropium, gycopyrronium and carmoterol</li><li>lvi. Daratropium, gycopyrronium and bambuterol</li><li>lvii. Daratropium, aclidinium and salmeterol</li><li>lviii. Daratropium, aclidinium and formoterol<!-- EPO <DP n="16"> --></li><li>lix. Daratropium, aclidinium and arformoterol</li><li>lx. Daratropium, aclidinium and indacaterol</li><li>lxi. Daratropium, aclidinium and olodaterol</li><li>lxii. Daratropium, aclidinium and vilanterol</li><li>lxiii. Daratropium, aclidinium and carmoterol</li><li>lxiv. Daratropium, aclidinium and bambuterol</li><li>lxv. Daratropium, oxitropium and salmeterol</li><li>lxvi. Daratropium, oxitropium and formoterol</li><li>lxvii. Daratropium, oxitropium and arformoterol</li><li>lxviii. Daratropium, oxitropium and indacaterol</li><li>lxix. Daratropium, oxitropium and olodaterol</li><li>lxx. Daratropium, oxitropium and vilanterol</li><li>lxxi. Daratropium, oxitropium and carmoterol</li><li>lxxii. Daratropium, oxitropium and bambuterol</li><li>lxxiii. Indacaterol, tirotropium and salmeterol</li><li>lxxiv. Indacaterol, tirotropium and formoterol</li><li>lxxv. Indacaterol, tirotropium and arformoterol</li><li>lxxvi. Indacaterol, tirotropium and olodaterol</li><li>lxxvii. Indacaterol, tirotropium and vilanterol</li><li>lxxviii. Indacaterol, tirotropium and carmoterol</li><li>lxxix. Indacaterol, tirotropium and bambuterol</li><li>lxxx. Indacaterol, glycopyrronium and salmeterol</li><li>lxxxi. Indacaterol, glycopyrronium and formoterol</li><li>lxxxii. Indacaterol, glycopyrronium and arformoterol</li><li>lxxxiii. Indacaterol, glycopyrronium and olodaterol</li><li>lxxxiv. Indacaterol, glycopyrronium and vilanterol</li><li>lxxxv. Indacaterol, glycopyrronium and carmoterol</li><li>lxxxvi. Indacaterol, glycopyrronium and bambuterol</li><li>lxxxvii. Indacaterol, aclidinium and salmeterol</li><li>lxxxviii. Indacaterol, aclidinium and formoterol</li><li>lxxxix. Indacaterol, aclidinium and arformoterol</li><li>xc. Indacaterol, aclidinium and olodaterol</li><li>xci. Indacaterol, aclidinium and vilanterol</li><li>xcii. Indacaterol, aclidinium and carmoterol</li><li>xciii. Indacaterol, aclidinium and bambuterol</li><li>xciv. Indacaterol, oxitropium and salmeterol</li><li>xcv. Indacaterol, oxitropium and formoterol<!-- EPO <DP n="17"> --></li><li>xcvi. Indacaterol, oxitropium and arformoterol</li><li>xcvii. Indacaterol, oxitropium and olodaterol</li><li>xcviii. Indacaterol, oxitropium and vilanterol</li><li>xcix. Indacaterol, oxitropium and carmoterol</li><li>c. Indacaterol, oxitropium and bambuterol</li><li>ci. Vilanterol, tiotropium and salmeterol</li><li>cii. Vilanterol, tiotropium and formoterol</li><li>ciii. Vilanterol, tiotropium and arformoterol</li><li>civ. Vilanterol, tiotropium and indacaterol</li><li>cv. Vilanterol, tiotropium and olodaterol</li><li>cvi. Vilanterol, tiotropium and carmoterol</li><li>cvii. Vilanterol, tiotropium and bambuterol</li><li>cviii. Vilanterol, glycopyrronium and salmeterol</li><li>cix. Vilanterol, glycopyrronium and formoterol</li><li>cx. Vilanterol, glycopyrronium and arformoterol</li><li>cxi. Vilanterol, glycopyrronium and indacaterol</li><li>cxii. Vilanterol, glycopyrronium and olodaterol</li><li>cxiii. Vilanterol, glycopyrronium and carmoterol</li><li>cxiv. Vilanterol, glycopyrronium and bambuterol</li><li>cxv. Vilanterol, aclidinium and salmeterol</li><li>cxvi. Vilanterol, aclidinium and formoterol</li><li>cxvii. Vilanterol, aclidinium and arformoterol</li><li>cxviii. Vilanterol, aclidinium and indacaterol</li><li>cxix. Vilanterol, aclidinium and olodaterol</li><li>cxx. Vilanterol, aclidinium and carmoterol</li><li>cxxi. Vilanterol, aclidinium and bambuterol</li><li>cxxii. Vilanterol, oxitropium and salmeterol</li><li>cxxiii. Vilanterol, oxitropium and formoterol</li><li>cxxiv. Vilanterol, oxitropium and arformoterol</li><li>cxxv. Vilanterol, oxitropium and indacaterol</li><li>cxxvi. Vilanterol, oxitropium and olodaterol</li><li>cxxvii. Vilanterol, oxitropium and carmoterol</li><li>cxxviii. Vilanterol, oxitropium and bambuterol</li><li>cxxix. Carmoterol, tiotropium and salmeterol</li><li>cxxx. Carmoterol, tiotropium and formoterol</li><li>cxxxi. Carmoterol, tiotropium and arformoterol</li><li>cxxxii. Carmoterol, tiotropium and indacaterol<!-- EPO <DP n="18"> --></li><li>cxxxiii. Carmoterol, tiotropium and olodaterol</li><li>cxxxiv. Carmoterol, tiotropium and vilanterol</li><li>cxxxv. Carmoterol, tiotropium and bambuterol</li><li>cxxxvi. Carmoterol, glycopyrronium and salmeterol</li><li>cxxxvii.Carmoterol, glycopyrronium and formoterol</li><li>cxxxviii. Carmoterol, glycopyrronium and arformoterol</li><li>cxxxix. Carmoterol, glycopyrronium and indacaterol</li><li>cxl. Carmoterol, glycopyrronium and olodaterol</li><li>cxli. Carmoterol, glycopyrronium and vilanterol</li><li>cxlii. Carmoterol, glycopyrronium and bambuterol</li><li>cxliii. Carmoterol, aclidinium and salmeterol</li><li>cxliv. Carmoterol, aclidinium and formoterol</li><li>cxlv. Carmoterol, aclidinium and arformoterol</li><li>cxlvi. Carmoterol, aclidinium and indacaterol</li><li>cxlvii. Carmoterol, aclidinium and olodaterol</li><li>cxlviii. Carmoterol, aclidinium and vilanterol</li><li>cxlix. Carmoterol, aclidinium and bambuterol</li><li>cl. Carmoterol, oxitropium and salmeterol</li><li>cli. Carmoterol, oxitropium and formoterol</li><li>clii. Carmoterol, oxitropium and arformoterol</li><li>cliii. Carmoterol, oxitropium and indacaterol</li><li>cliv. Carmoterol, oxitropium and olodaterol</li><li>clv. Carmoterol, oxitropium and vilanterol</li><li>clvi. Carmoterol, oxitropium and bambuterol</li><li>clvii. Olodaterol, tiotropium and salmeterol</li><li>clviii. Olodaterol, tiotropium and formoterol</li><li>clix. Olodaterol, tiotropium and arformoterol</li><li>clx. Olodaterol, tiotropium and indacaterol</li><li>clxi. Olodaterol, tiotropium and vilanterol</li><li>clxii. Olodaterol, tiotropium and bambuterol</li><li>clxiii. Olodaterol, glycopyrronium and salmeterol</li><li>clxiv. Olodaterol, glycopyrronium and formoterol</li><li>clxv. Olodaterol, glycopyrronium and arformoterol</li><li>clxvi. Olodaterol, glycopyrronium and indacaterol</li><li>clxvii. Olodaterol, glycopyrronium and vilanterol</li><li>clxviii. Olodaterol, glycopyrronium and bambuterol</li><li>clxix. Olodaterol, aclidinium and salmeterol<!-- EPO <DP n="19"> --></li><li>clxx. Olodaterol, aclidinium and formoterol</li><li>clxxi. Olodaterol, aclidinium and arformoterol</li><li>clxxii. Olodaterol, aclidinium and indacaterol</li><li>clxxiii. Olodaterol, aclidinium and vilanterol</li><li>clxxiv. Olodaterol, aclidinium and bambuterol</li><li>clxxv. Olodaterol, oxitropium and salmeterol</li><li>clxxvi. Olodaterol, oxitropium and formoterol</li><li>clxxvii. Olodaterol, oxitropium and arformoterol</li><li>clxxviii. Olodaterol, oxitropium and indacaterol</li><li>clxxix. Olodaterol, oxitropium and vilanterol</li><li>clxxx. Olodaterol, oxitropium and bambuterol</li></ul>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0065" num="0065">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of;
<ul><li>i. Aclidinum, tiotropium and salbutamol</li><li>ii. Aclidinum, tiotropium and levosalbutamol</li><li>iii. Aclidinum, tiotropium and terbutaline</li><li>iv. Aclidinum, tiotropium and pirbutarol</li><li>v. Aclidinum, tiotropium and procaterol</li><li>vi. Aclidinum, tiotropium and fenoterol</li><li>vii. Aclidinum, tiotropium and ritodrine</li><li>viii. Aclidinum, tiotropium and bitolterol</li><li>ix. Aclidinum, tiotropium and metaproterenol</li><li>x. Aclidinum, glycopyrronium and salbutamol</li><li>xi. Aclidinum, glycopyrronium and levosalbutamol</li><li>xii. Aclidinum, glycopyrronium and terbutaline</li><li>xiii. Aclidinum, glycopyrronium and pirbuterol</li><li>xiv. Aclidinum, glycopyrronium and procaterol</li><li>xv. Aclidinum, glycopyrronium and fenoterol</li><li>xvi. Aclidinum, glycopyrronium and bitolterol</li><li>xvii. Aclidinum, glycopyrronium and ritodrine</li><li>xviii. Aclidinum, glycopyrronium and metaproterenol</li><li>xix. Aclidinum, ipratropium and salbutamol</li><li>xx. Aclidinum, ipratropium and levosalbutamol<!-- EPO <DP n="20"> --></li><li>xxi. Aclidinum, ipratropium and terbutaline</li><li>xxii. Aclidinum, ipratropium and pirbuterol</li><li>xxiii. Aclidinum, ipratropium and procaterol</li><li>xxiv. Aclidinum, ipratropium and fenoterol</li><li>xxv. Aclidinum, ipratropium and bitolterol</li><li>xxvi. Aclidinum, ipratropium and ritodrine</li><li>xxvii. Aclidinum, ipratropium and metaproterenol</li><li>xxviii. Aclidinum, oxitropium and salbutamol</li><li>xxix. Aclidinum, oxitropium and levosalbutamol</li><li>xxx. Aclidinum, oxitropium and terbutaline</li><li>xxxi. Aclidinum, oxitropium and pirbuterol</li><li>xxxii. Aclidinum, oxitropium and procaterol</li><li>xxxiii. Aclidinum, oxitropium and fenoterol</li><li>xxxiv. Aclidinum, oxitropium and bitolterol</li><li>xxxv. Aclidinum, oxitropium and ritodrine</li><li>xxxvi. Aclidinum, oxitropium and metaproterenol</li><li>xxxvii. Glycopyrronium, tiotropium and salbutamol</li><li>xxxviii. Glycopyrronium, tiotropium and levosalbutamol</li><li>xxxix. Glycopyrronium, tiotropium and terbutaline</li><li>xl. Glycopyrronium, tiotropium and pirbuterol</li><li>xli. Glycopyrronium, tiotropium and procaterol</li><li>xlii. Glycopyrronium, tiotropium and fenoterol</li><li>xliii. Glycopyrronium, tiotropium and bitolterol</li><li>xliv. Glycopyrronium, tiotropium and ritodrine</li><li>xlv. Glycopyrronium, tiotropium and metaproterenol</li><li>xlvi. Glycopyrronium, ipratropium and salbutamol</li><li>xlvii. Glycopyrronium, ipratropium and levosalbutamol</li><li>xlviii. Glycopyrronium, ipratropium and terbutaline</li><li>xlix. Glycopyrronium, ipratropium and pirbuterol</li><li>l. Glycopyrronium, ipratropium and procaterol</li><li>li. Glycopyrronium, ipratropium and fenoterol</li><li>lii. Glycopyrronium, ipratropium and bitolterol</li><li>liii. Glycopyrronium, ipratropium and ritodrine</li><li>liv. Glycopyrronium, ipratropium and metaproterenol</li><li>lv. Glycopyrronium, oxitropium and salbutamol</li><li>lvi. Glycopyrronium, oxitropium and levosalbutamol</li><li>lvii. Glycopyrronium, oxitropium and terbutaline<!-- EPO <DP n="21"> --></li><li>lviii. Glycopyrronium, oxitropium and pirbuterol</li><li>lix. Glycopyrronium, oxitropium and procaterol</li><li>lx. Glycopyrronium, oxitropium and fenoterol</li><li>lxi. Glycopyrronium, oxitropium and bitolterol</li><li>lxii. Glycopyrronium, oxitropium and ritodrine</li><li>lxiii. Glycopyrronium, oxitropium and metaproterenol</li><li>lxiv. Daratropium, tiotropium and salbutamol</li><li>lxv. Daratropium, tiotropium and levosalbutamol</li><li>lxvi. Daratropium, tiotropium and terbutaline</li><li>lxvii. Daratropium, tiotropium and pirbuterol</li><li>lxviii. Daratropium, tiotropium and procaterol</li><li>lxix. Daratropium, tiotropium and fenoterol</li><li>lxx. Daratropium, tiotropium and bitolterol</li><li>lxxi. Daratropium, tiotropium and ritodrine</li><li>lxxii. Daratropium, tiotropium and metaproterenol</li><li>lxxiii. Daratropium, aclidinium and salbutamol</li><li>lxxiv. Daratropium, aclidinium and levosalbutamol</li><li>lxxv. Daratropium, aclidinium and terbutaline</li><li>lxxvi. Daratropium, aclidinium and pirbuterol</li><li>lxxvii. Daratropium, aclidinium and procaterol</li><li>lxxviii. Daratropium, aclidinium and fenoterol</li><li>lxxix. Daratropium, aclidinium and bitolterol</li><li>lxxx. Daratropium, aclidinium and ritodrine</li><li>lxxxi. Daratropium, aclidinium and metaproterenol</li><li>lxxxii. Daratropium, glycopyrronium and salbutamol</li><li>lxxxiii. Daratropium, glycopyrronium and levosalbutamol</li><li>lxxxiv. Daratropium, glycopyrronium and terbutaline</li><li>lxxxv. Daratropium, glycopyrronium and pirbuterol</li><li>lxxxvi. Daratropium, glycopyrronium and procaterol</li><li>lxxxvii. Daratropium, glycopyrronium and fenoterol</li><li>lxxxviii. Daratropium, glycopyrronium and bitolterol</li><li>lxxxix. Daratropium, glycopyrronium and ritodrine</li><li>xc. Daratropium, glycopyrronium and metaproterenol</li><li>xci. Daratropium, ipratropium and salbutamol</li><li>xcii. Daratropium, ipratropium and levosalbutamol</li><li>xciii. Daratropium, ipratropium and terbutaline</li><li>xciv. Daratropium, ipratropium and pirbuterol<!-- EPO <DP n="22"> --></li><li>xcv. Daratropium, ipratropium and procaterol</li><li>xcvi. Daratropium, ipratropium and fenoterol</li><li>xcvii. Daratropium, ipratropium and bitolterol</li><li>xcviii. Daratropium, ipratropium and ritodrine</li><li>xcix. Daratropium, ipratropium and metaproterenol</li><li>c. Daratropium, oxitropium and salbutamol</li><li>ci. Daratropium, oxitropium and levosalbutamol</li><li>cii. Daratropium, oxitropium and terbutaline</li><li>ciii. Daratropium, oxitropium and pirbuterol</li><li>civ. Daratropium, oxitropium and procaterol</li><li>cv. Daratropium, oxitropium and fenoterol</li><li>cvi. Daratropium, oxitropium and bitolterol</li><li>cvii. Daratropium, oxitropium and ritodrine</li><li>cviii. Daratropium, oxitropium and metaproterenol</li><li>cix. Indacaterol, tirotropium and salbutamol</li><li>cx. Indacaterol, tirotropium and levosalbutamol</li><li>cxi. Indacaterol, tirotropium and terbutaline</li><li>cxii. Indacaterol, tirotropium and pirbuterol</li><li>cxiii. Indacaterol, tirotropium and procaterol</li><li>cxiv. Indacaterol, tirotropium and fenoterol</li><li>cxv. Indacaterol, tirotropium and bitolterol</li><li>cxvi. Indacaterol, tirotropium and ritodrine</li><li>cxvii. Indacaterol, tirotropium and metaproterenol</li><li>cxviii. Indacaterol, glycopyrronium and salbutamol</li><li>cxix. Indacaterol, glycopyrronium and levosalbutamol</li><li>cxx. Indacaterol, glycopyrronium and terbutaline</li><li>cxxi. Indacaterol, glycopyrronium and pirbuterol</li><li>cxxii. Indacaterol, glycopyrronium and procaterol</li><li>cxxiii. Indacaterol, glycopyrronium and fenoterol</li><li>cxxiv. Indacaterol, glycopyrronium and bitolterol</li><li>cxxv. Indacaterol, glycopyrronium and ritodrine</li><li>cxxvi. Indacaterol, glycopyrronium and metaproterenol</li><li>cxxvii. Indacaterol, aclidinium and salbutamol</li><li>cxxviii. Indacaterol, aclidinium and levosalbutamol</li><li>cxxix. Indacaterol, aclidinium and terbutaline</li><li>cxxx. Indacaterol, aclidinium and pirbuterol</li><li>cxxxi. Indacaterol, aclidinium and procaterol<!-- EPO <DP n="23"> --></li><li>cxxxii. Indacaterol, aclidinium and fenoterol</li><li>cxxxiii. Indacaterol, aclidinium and bitolterol</li><li>cxxxiv. Indacaterol, aclidinium and ritodrine</li><li>cxxxv. Indacaterol, aclidinium and metaproterenol</li><li>cxxxvi. Indacaterol, ipratropium and salbutamol</li><li>cxxxvii. Indacaterol, ipratropium and levosalbutamol</li><li>cxxxviii. Indacaterol, ipratropium and terbutaline</li><li>cxxxix. Indacaterol, ipratropium and pirbuterol</li><li>cxl. Indacaterol, ipratropium and procaterol</li><li>cxli. Indacaterol, ipratropium and fenoterol</li><li>cxlii. Indacaterol, ipratropium and bitolterol</li><li>cxliii. Indacaterol, ipratropium and ritodrine</li><li>cxliv. Indacaterol, ipratropium and metaproterenol</li><li>cxlv. Indacaterol, oxitropium and salbutamol</li><li>cxlvi. Indacaterol, oxitropium and levosalbutamol</li><li>cxlvii. Indacaterol, oxitropium and terbutaline</li><li>cxlviii. Indacaterol, oxitropium and pirbuterol</li><li>cxlix. Indacaterol, oxitropium and procaterol</li><li>cl. Indacaterol, oxitropium and fenoterol</li><li>cli. Indacaterol, oxitropium and bitolterol</li><li>clii. Indacaterol, oxitropium and ritodrine</li><li>cliii. Indacaterol, oxitropium and metaproterenol</li><li>cliv. Vilanterol, tiotropium and salbutamol</li><li>clv. Vilanterol, tiotropium and levosalbutamol</li><li>clvi. Vilanterol, tiotropium and terbutaline</li><li>clvii. Vilanterol, tiotropium and pirbuterol</li><li>clviii. Vilanterol, tiotropium and procaterol</li><li>clix. Vilanterol, tiotropium and fenoterol</li><li>clx. Vilanterol, tiotropium and bitolterol</li><li>clxi. Vilanterol, tiotropium and ritodrine</li><li>clxii. Vilanterol, tiotropium and metaproterenol</li><li>clxiii. Vilanterol, glycopyrronium and salbutamol</li><li>clxiv. Vilanterol, glycopyrronium and levosalbutamol</li><li>clxv. Vilanterol, glycopyrronium and terbutaline</li><li>clxvi. Vilanterol, glycopyrronium and pirbuterol</li><li>clxvii. Vilanterol, glycopyrronium and procaterol</li><li>clxviii. Vilanterol, glycopyrronium and fenoterol<!-- EPO <DP n="24"> --></li><li>clxix. Vilanterol, glycopyrronium and bitolterol</li><li>clxx. Vilanterol, glycopyrronium and ritodrine</li><li>clxxi. Vilanterol, glycopyrronium and metaproterenol</li><li>clxxii. Vilanterol, ipratropium and salbutamol</li><li>clxxiii. Vilanterol, ipratropium and levosalbutamol</li><li>clxxiv. Vilanterol, ipratropium and terbutaline</li><li>clxxv. Vilanterol, ipratropium and pirbuterol</li><li>clxxvi. Vilanterol, ipratropium and procaterol</li><li>clxxvii. Vilanterol, ipratropium and fenoterol</li><li>clxxviii. Vilanterol, ipratropium and bitolterol</li><li>clxxix. Vilanterol, ipratropium and ritodrine</li><li>clxxx. Vilanterol, ipratropium and metaproterenol</li><li>clxxxi. Vilanterol, aclidinium and salbutamol</li><li>clxxxii. Vilanterol, aclidinium and levosalbutamol</li><li>clxxxiii. Vilanterol, aclidinium and terbutaline</li><li>clxxxiv.Vilanterol, aclidinium and pirbuterol</li><li>clxxxv. Vilanterol, aclidinium and procaterol</li><li>clxxxvi.Vilanterol, aclidinium and fenoterol</li><li>clxxxvii. Vilanterol, aclidinium and bitolterol</li><li>clxxxviii. Vilanterol, aclidinium and ritodrine</li><li>clxxxix.Vilanterol, aclidinium and metaproterenol</li><li>cxc. Vilanterol, oxitropium and salbutamol</li><li>cxci. Vilanterol, oxitropium and levosalbutamol</li><li>cxcii. Vilanterol, oxitropium and terbutaline</li><li>cxciii. Vilanterol, oxitropium and pirbuterol</li><li>cxciv. Vilanterol, oxitropium and procaterol</li><li>cxcv. Vilanterol, oxitropium and fenoterol</li><li>cxcvi. Vilanterol, oxitropium and bitolterol</li><li>cxcvii. Vilanterol, oxitropium and ritodrine</li><li>cxcviii. Vilanterol, oxitropium and metaproterenol</li><li>cxcix. Carmoterol, tiotropium and salbutamol</li><li>cc. Carmoterol, tiotropium and levosalbutamol</li><li>cci. Carmoterol, tiotropium and terbutaline</li><li>ccii. Carmoterol, tiotropium and pirbuterol</li><li>cciii. Carmoterol, tiotropium and procaterol</li><li>cciv. Carmoterol, tiotropium and fenoterol</li><li>ccv. Carmoterol, tiotropium and bitolterol<!-- EPO <DP n="25"> --></li><li>ccvi. Carmoterol, tiotropium and ritodrine</li><li>ccvii. Carmoterol, tiotropium and metaproterenol</li><li>ccviii. Carmoterol, ipratropium and levosalbutamol</li><li>ccix. Carmoterol, ipratropium and salbutamol</li><li>ccx. Carmoterol, ipratropium and terbutaline</li><li>ccxi. Carmoterol, ipratropium and pirbuterol</li><li>ccxii. Carmoterol, ipratropium and procaterol</li><li>ccxiii. Carmoterol, ipratropium and fenoterol</li><li>ccxiv. Carmoterol, ipratropium and bitolterol</li><li>ccxv. Carmoterol, ipratropium and ritodrine</li><li>ccxvi. Carmoterol, ipratropium and metaproterenol</li><li>ccxvii. Carmoterol, aclidinum and levosalbutamol</li><li>ccxviii. Carmoterol, aclidinum and salbutamol</li><li>ccxix. Carmoterol, aclidinum and terbutaline</li><li>ccxx. Carmoterol, aclidinum and pirbuterol</li><li>ccxxi. Carmoterol, aclidinum and procaterol</li><li>ccxxii. Carmoterol, aclidinum and fenoterol</li><li>ccxxiii. Carmoterol, aclidinum and bitolterol</li><li>ccxxiv. Carmoterol, aclidinum and ritodrine</li><li>ccxxv. Carmoterol, aclidinum and metaproterenol</li><li>ccxxvi. Carmoterol, oxitropium and salbutamol</li><li>ccxxvii.Carmoterol, oxitropium and levosalbutamol</li><li>ccxxviii. Carmoterol, oxitropium and terbutaline</li><li>ccxxix. Carmoterol, oxitropium and pirbuterol</li><li>ccxxx. Carmoterol, oxitropium and procaterol</li><li>ccxxxi. Carmoterol, oxitropium and fenoterol</li><li>ccxxxii.Carmoterol, oxitropium and bitolterol</li><li>ccxxxiii. Carmoterol, oxitropium and ritodrine</li><li>ccxxxiv. Carmoterol, oxitropium and metaproterenol</li><li>ccxxxv. Olodaterol, tiotropium and salbutamol</li><li>ccxxxvi. Olodaterol, tiotropium and levosalbutamol</li><li>ccxxxvii. Olodaterol, tiotropium and terbutaline</li><li>ccxxxviii. Olodaterol, tiotropium and pirbuterol</li><li>ccxxxix. Olodaterol, tiotropium and procaterol</li><li>ccxl. Olodaterol, tiotropium and fenoterol</li><li>ccxli. Olodaterol, tiotropium and bitolterol</li><li>ccxlii. Olodaterol, tiotropium and ritodrine<!-- EPO <DP n="26"> --></li><li>ccxliii. Olodaterol, tiotropium and metaproterenol</li><li>ccxliv. Olodaterol, ipratropium and salbutamol</li><li>ccxlv. Olodaterol, ipratropium and levosalbutamol</li><li>ccxlvi. Olodaterol, ipratropium and terbutaline</li><li>ccxlvii. Olodaterol, ipratropium and pirbuterol</li><li>ccxlviii. Olodaterol, ipratropium and procaterol</li><li>ccxlix. Olodaterol, ipratropium and fenoterol</li><li>ccl. Olodaterol, ipratropium and bitolterol</li><li>ccli. Olodaterol, ipratropium and ritodrine</li><li>cclii. Olodaterol, ipratropium and metaproterenol</li><li>ccliii. Olodaterol, aclidinum and salbutamol</li><li>ccliv. Olodaterol, aclidinum and levosalbutamol</li><li>cclv. Olodaterol, aclidinum and terbutaline</li><li>cclvi. Olodaterol, aclidinum and pirbuterol</li><li>cclvii. Olodaterol, aclidinum and procaterol</li><li>cclviii. Olodaterol, aclidinum and fenoterol</li><li>cclix. Olodaterol, aclidinum and bitolterol</li><li>cclx. Olodaterol, aclidinum and ritodrine</li><li>cclxi. Olodaterol, aclidinum and metaproterenol</li><li>cclxii. Olodaterol, glycopyrronium and salbutamol</li><li>cclxiii. Olodaterol, glycopyrronium and levosalbutamol</li><li>cclxiv. Olodaterol, glycopyrronium and terbutaline</li><li>cclxv. Olodaterol, glycopyrronium and pirbuterol</li><li>cclxvi. Olodaterol, glycopyrronium and procaterol</li><li>cclxvii. Olodaterol, glycopyrronium and fenoterol</li><li>cclxviii. Olodaterol, glycopyrronium and bitolterol</li><li>cclxix. Olodaterol, glycopyrronium and ritodrine</li><li>cclxx. Olodaterol, glycopyrronium and metaproterenol</li><li>cclxxi. Olodaterol, oxitropium and salbutamol</li><li>cclxxii. Olodaterol, oxitropium and levosalbutamol</li><li>cclxxiii. Olodaterol, oxitropium and terbutaline</li><li>cclxxiv. Olodaterol, oxitropium and pirbuterol</li><li>cclxxv. Olodaterol, oxitropium and procaterol</li><li>cclxxvi. Olodaterol, oxitropium and fenoterol</li><li>cclxxvii. Olodaterol, oxitropium and bitolterol</li><li>cclxxviii. Olodaterol, oxitropium and ritodrine</li><li>cclxxix. Olodaterol, oxitropium and metaproterenol<!-- EPO <DP n="27"> --> wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</li></ul></p><p id="p0066" num="0066">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of;
<ul><li>i. Aclidinum, tiotropium and fluticasone</li><li>ii. Aclidinum, tiotropium and ciclesonide</li><li>iii. Aclidinum, tiotropium and budesonide</li><li>iv. Aclidinum, tiotropium and mometasone</li><li>v. Aclidinum, tiotropium and beclomethasone</li><li>vi. Aclidinum, tiotropium and triamcinolone</li><li>vii. Aclidinum, tiotropium and flunisolide</li><li>viii. Aclidinum, tiotropium and dexomethasone</li><li>ix. Daratropium, tiotropium and fluticasone</li><li>x. Daratropium, tiotropium and ciclesonide</li><li>xi. Daratropium, tiotropium and budesonide</li><li>xii. Daratropium, tiotropium and mometasone</li><li>xiii. Daratropium, tiotropium and beclamethasone</li><li>xiv. Daratropium, tiotropium and triamcinolone</li><li>xv. Daratropium, tiotropium and flunisolide</li><li>xvi. Daratropium, tiotropium and dexomethasone</li><li>xvii. Indacaterol, tiotropium and fluticasone</li><li>xviii. Indacaterol, tiotropium and budesonide</li><li>xix. Indacaterol, tiotropium and ciclesonide</li><li>xx. Indacaterol, tiotropium and mometasone</li><li>xxi. Indacaterol, tiotropium and beclamethasone</li><li>xxii. Indacaterol, tiotropium and triamcinolone</li><li>xxiii. Indacaterol, tiotropium and flunisolide</li><li>xxiv. Indacaterol, tiotropium and dexomethasone</li><li>xxv. Vilanterol, tiotropium and ciclesonide</li><li>xxvi. vilanterol, tiotropium and fluticasone</li><li>xxvii. vilanterol, tiotropium and budesonide</li><li>xxviii. vilanterol, tiotropium and mometasone</li><li>xxix. vilanterol, tiotropium and beclamethasone</li><li>xxx. vilanterol, tiotropium and triamcinolone<!-- EPO <DP n="28"> --></li><li>xxxi. vilanterol, tiotropium and flunisolide</li><li>xxxii. vilanterol, tiotropium and dexomethasone</li><li>xxxiii. carmoterol, tiotropium and budesonide</li><li>xxxiv. carmoterol, tiotropium and ciclesonide</li><li>xxxv. carmoterol, tiotropium and fluticasone</li><li>xxxvi. carmoterol, tiotropium and mometasone</li><li>xxxvii. carmoterol, tiotropium and beclamethasone</li><li>xxxviii. carmoterol, tiotropium and triamcinolone</li><li>xxxix. carmoterol, tiotropium and flunisolide</li><li>xl. carmoterol, tiotropium and dexomethasone</li><li>xli. Olodaterol, tiotropium and ciclesonide</li><li>xlii. Olodaterol, tiotropium and fluticasone</li><li>xliii. Olodaterol, tiotropium and budesonide</li><li>xliv. Olodaterol, tiotropium and mometasone</li><li>xlv. Olodaterol, tiotropium and beclamethasone</li><li>xlvi. Olodaterol, tiotropium and triamcinolone</li><li>xlvii. Olodaterol, tiotropium and flunisolide</li><li>xlviii. Olodaterol, tiotropium and dexomethasone</li></ul>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0067" num="0067">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of;
<ul><li>i. Aclidinium, salmeterol and salbutamol</li><li>ii. Aclidinium, salmeterol and levosalbutamol</li><li>iii. Aclidinium, formoterol and salbutamol</li><li>iv. Aclidinium, formoterol and levosalbutamol</li><li>v. Aclidinium, arformoterol and salbutamol</li><li>vi. Aclidinium, arformoterol and levosalbutamol</li><li>vii. Aclidinium, indacaterol and salbutamol</li><li>viii. Aclidinium, indacaterol and levosalbutamol</li><li>ix. Aclidinium, olodaterol and salbutamol</li><li>x. Aclidinium, olodaterol and levosalbutamol</li><li>xi. Aclidinium, vilanterol and salbutamol</li><li>xii. Aclidinium, vilanterol and levosalbutamol<!-- EPO <DP n="29"> --></li><li>xiii. Aclidinium, carmoterol and salbutamol</li><li>xiv. Aclidinium, carmoterol and levosalbutamol</li><li>xv. Aclidinium, bambuterol and salbutamol</li><li>xvi. Aclidinium, bambuterol and levosalbutamol</li><li>xvii. Glycopyrronium, indacaterol and salbutamol</li><li>xviii. Glycopyrronium, indacaterol and levosalbutamol</li><li>xix. Glycopyrronium, salmeterol and salbutamol</li><li>xx. Glycopyrronium, salmeterol and levosalbutamol</li><li>xxi. Glycopyrronium, formoterol and salbutamol</li><li>xxii. Glycopyrronium, formoterol and levosalbutamol</li><li>xxiii. Glycopyrronium, arformoterol and salbutamol</li><li>xxiv. Glycopyrronium, arformoterol and levosalbutamol</li><li>xxv. Glycopyrronium, carmoterol and salbutamol</li><li>xxvi. Glycopyrronium, carmoterol and levosalbutamol</li><li>xxvii. Glycopyrronium, olodaterol and salbutamol</li><li>xxviii. Glycopyrronium, olodaterol and levosalbutamol</li><li>xxix. Glycopyrronium, vilanterol and salbutamol</li><li>xxx. Glycopyrronium, vilanterol and levosalbutamol</li><li>xxxi. Glycopyrronium, bambuterol and salbutamol</li><li>xxxii. Glycopyrronium, bambuterol and levosalbutamol</li><li>xxxiii. Daratropium, indacaterol and salbutamol</li><li>xxxiv. Daratropium, indacaterol and levosalbutamol</li><li>xxxv. Daratropium, salmeterol and salbutamol</li><li>xxxvi. Daratropium, salmeterol and levosalbutamol</li><li>xxxvii. Daratropium, formoterol and salbutamol</li><li>xxxviii. Daratropium, formoterol and levosalbutamol</li><li>xxxix. Daratropium, carmoterol and salbutamol</li><li>xl. Daratropium, carmoterol and levosalbutamol</li><li>xli. Daratropium, olodaterol and salbutamol</li><li>xlii. Daratropium, olodaterol and levosalbutamol</li><li>xliii. Daratropium, vilanterol and salbutamol</li><li>xliv. Daratropium, vilanterol and levosalbutamol</li><li>xlv. Daratropium, bambuterol and salbutamol</li><li>xlvi. Daratropium, bambuterol and levosalbutamol</li><li>xlvii. Daratropium, arformoterol and salbutamol</li><li>xlviii. Daratropium, arformoterol and levosalbutamol</li></ul><!-- EPO <DP n="30"> -->
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0068" num="0068">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of;
<ul><li>i. Aclidinium, salmeterol and mometasone</li><li>ii. Aclidinium, salmeterol and fluticasone</li><li>iii. Aclidinium, salmeterol and budesonide</li><li>iv. Aclidinium, formoterol and mometasone</li><li>v. Aclidinium, formoterol and fluticasone</li><li>vi. Aclidinium, formoterol and budesonide</li><li>vii. Aclidinium, arformoterol and mometasone</li><li>viii. Aclidinium, arformoterol and fluticasone</li><li>ix. Aclidinium, arformoterol and budesonide</li><li>x. Aclidinium, indacaterol and mometasone</li><li>xi. Aclidinium, indacaterol and fluticasone</li><li>xii. Aclidinium, indacaterol and budesonide</li><li>xiii. Aclidinium, olodaterol and mometasone</li><li>xiv. Aclidinium, olodaterol and fluticasone</li><li>xv. Aclidinium, olodaterol and budesonide</li><li>xvi. Aclidinium, vilanterol and mometasone</li><li>xvii. Aclidinium, vilanterol and fluticasone</li><li>xviii. Aclidinium, vilanterol and budesonide</li><li>xix. Aclidinium, carmoterol and mometasone</li><li>xx. Aclidinium, carmoterol and fluticasone</li><li>xxi. Aclidinium, carmoterol and budesonide</li><li>xxii. Aclidinium, bambuterol and mometasone</li><li>xxiii. Aclidinium, bambuterol and fluticasone</li><li>xxiv. Aclidinium, bambuterol and budesonide</li><li>xxv. Glycopyrronium, indacaterol and mometasone</li><li>xxvi. Glycopyrronium, indacaterol and fluticasone</li><li>xxvii. Glycopyrronium, indacaterol and budesonide</li><li>xxviii. Glycopyrronium, salmeterol and mometasone</li><li>xxix. Glycopyrronium, salmeterol and fluticasone</li><li>xxx. Glycopyrronium, salmeterol and budesonide<!-- EPO <DP n="31"> --></li><li>xxxi. Glycopyrronium, formoterol and mometasone</li><li>xxxii. Glycopyrronium, formoterol and fluticasone</li><li>xxxiii. Glycopyrronium, formoterol and budesonide</li><li>xxxiv. Glycopyrronium, arformoterol and mometasone</li><li>xxxv. Glycopyrronium, arformoterol and fluticasone</li><li>xxxvi. Glycopyrronium, arformoterol and budesonide</li><li>xxxvii. Glycopyrronium, carmoterol and mometasone</li><li>xxxviii. Glycopyrronium, carmoterol and fluticasone</li><li>xxxix. Glycopyrronium, carmoterol and budesonide</li><li>xl. Glycopyrronium, olodaterol and mometasone</li><li>xli. Glycopyrronium, olodaterol and fluticasone</li><li>xlii. Glycopyrronium, olodaterol and budesonide</li><li>xliii. Glycopyrronium, vilanterol and mometasone</li><li>xliv. Glycopyrronium, vilanterol and fluticasone</li><li>xlv. Glycopyrronium, vilanterol and budesonide</li><li>xlvi. Glycopyrronium, bambuterol and mometasone</li><li>xlvii. Glycopyrronium, bambuterol and fluticasone</li><li>xlviii. Glycopyrronium, bambuterol and budesonide</li><li>xlix. Daratropium, indacaterol and mometasone</li><li>l. Daratropium, indacaterol and fluticasone</li><li>li. Daratropium, indacaterol and budesonide</li><li>lii. Daratropium, salmeterol and mometasone</li><li>liii. Daratropium, salmeterol and fluticasone</li><li>liv. Daratropium, salmeterol and budesonide</li><li>lv. Daratropium, formoterol and mometasone</li><li>lvi. Daratropium, formoterol and fluticasone</li><li>lvii. Daratropium, formoterol and budesonide</li><li>lviii. Daratropium, carmoterol and mometasone</li><li>lix. Daratropium, carmoterol and fluticasone</li><li>lx. Daratropium, carmoterol and budesonide</li><li>lxi. Daratropium, olodaterol and mometasone</li><li>lxii. Daratropium, olodaterol and fluticasone</li><li>lxiii. Daratropium, olodaterol and budesonide</li><li>lxiv. Daratropium, vilanterol and mometasone</li><li>lxv. Daratropium, vilanterol and fluticasone</li><li>lxvi. Daratropium, vilanterol and budesonide</li><li>lxvii. Daratropium, bambuterol and mometasone<!-- EPO <DP n="32"> --></li><li>lxviii. Daratropium, bambuterol and fluticasone</li><li>lxix. Daratropium, bambuterol and budesonide</li><li>lxx. Daratropium, arformoterol and mometasone</li><li>lxxi. Daratropium, arformoterol and fluticasone</li><li>lxxii. Daratropium, arformoterol and budesonide</li><li>lxxiii. Indacaterol, salmeterol and mometasone</li><li>lxxiv. Indacaterol, salmeterol and fluticasone</li><li>lxxv. Indacaterol, salmeterol and budesonide</li><li>lxxvi. Indacaterol, formoterol and mometasone</li><li>lxxvii. Indacaterol, formoterol and fluticasone</li><li>lxxviii. Indacaterol, formoterol and budesonide</li><li>lxxix. Indacaterol, arformoterol and mometasone</li><li>lxxx. Indacaterol, arformoterol and fluticasone</li><li>lxxxi. Indacaterol, arformoterol and budesonide</li><li>lxxxii. Indacaterol, olodaterol and mometasone</li><li>lxxxiii. Indacaterol, olodaterol and fluticasone</li><li>lxxxiv. Indacaterol, olodaterol and budesonide</li><li>lxxxv. Indacaterol, vilanterol and mometasone</li><li>lxxxvi. Indacaterol, vilanterol and fluticasone</li><li>lxxxvii. Indacaterol, vilanterol and budesonide</li><li>lxxxviii. Indacaterol, carmeterol and mometasone</li><li>lxxxix. Indacaterol, carmeterol and fluticasone</li><li>xc. Indacaterol, carmeterol and budesonide</li><li>xci. Indacaterol, bambuterol and mometasone</li><li>xcii. Indacaterol, bambuterol and fluticasone</li><li>xciii. Indacaterol, bambuterol and budesonide</li><li>xciv. Vilanterol, salmeterol and mometasone</li><li>xcv. Vilanterol, salmeterol and fluticasone</li><li>xcvi. Vilanterol, salmeterol and budesonide</li><li>xcvii. Vilanterol, formoterol and mometasone</li><li>xcviii. Vilanterol, formoterol and fluticasone</li><li>xcix. Vilanterol, formoterol and budesonide</li><li>c. Vilanterol, arformoterol and mometasone</li><li>ci. Vilanterol, arformoterol and fluticasone</li><li>cii. Vilanterol, arformoterol and budesonide</li><li>ciii. Vilanterol, olodaterol and mometasone</li><li>civ. Vilanterol, olodaterol and fluticasone<!-- EPO <DP n="33"> --></li><li>cv. Vilanterol, olodaterol and budesonide</li><li>cvi. Vilanterol, carmeterol and mometasone</li><li>cvii. Vilanterol, carmeterol and fluticasone</li><li>cviii. Vilanterol, carmeterol and budesonide</li><li>cix. Vilanterol, bambuterol and mometasone</li><li>cx. Vilanterol, bambuterol and fluticasone</li><li>cxi. Vilanterol, bambuterol and budesonide</li><li>cxii. Vilanterol, indacaterol and mometasone</li><li>cxiii. Vilanterol, indacaterol and fluticasone</li><li>cxiv. Vilanterol, indacaterol and budesonide</li><li>cxv. Carmeterol, salmeterol and mometasone</li><li>cxvi. Carmeterol, salmeterol and fluticasone</li><li>cxvii. Carmeterol, salmeterol and budesonide</li><li>cxviii. Carmeterol, formoterol and mometasone</li><li>cxix. Carmeterol, formoterol and fluticasone</li><li>cxx. Carmeterol, formoterol and budesonide</li><li>cxxi. Carmeterol, arformoterol and mometasone</li><li>cxxii. Carmeterol, arformoterol and fluticasone</li><li>cxxiii. Carmeterol, arformoterol and budesonide</li><li>cxxiv. Carmeterol, indaceterol and mometasone</li><li>cxxv. Carmeterol, indaceterol and fluticasone</li><li>cxxvi. Carmeterol, indaceterol and budesonide</li><li>cxxvii. Carmeterol, olodaterol and mometasone</li><li>cxxviii. Carmeterol, olodaterol and fluticasone</li><li>cxxix. Carmeterol, olodaterol and budesonide</li><li>cxxx. Carmeterol, vilanterol and mometasone</li><li>cxxxi. Carmeterol, vilanterol and fluticasone</li><li>cxxxii. Carmeterol, vilanterol and budesonide</li><li>cxxxiii. Carmeterol, bambuterol and mometasone</li><li>cxxxiv. Carmeterol, bambuterol and fluticasone</li><li>cxxxv. Carmeterol, bambuterol and budesonide</li><li>cxxxvi. Olodaterol, salmeterol and mometasone</li><li>cxxxvii. Olodaterol, salmeterol and fluticasone</li><li>cxxxviii. Olodaterol, salmeterol and budesonide</li><li>cxxxix. Olodaterol, formoterol and mometasone</li><li>cxl. Olodaterol, formoterol and fluticasone</li><li>cxli. Olodaterol, formoterol and budesonide<!-- EPO <DP n="34"> --></li><li>cxlii. Olodaterol, arformoterol and mometasone</li><li>cxliii. Olodaterol, arformoterol and fluticasone</li><li>cxliv. Olodaterol, arformoterol and budesonide</li><li>cxlv. Olodaterol, indaceterol and mometasone</li><li>cxlvi. Olodaterol, indaceterol and fluticasone</li><li>cxlvii. Olodaterol, indaceterol and budesonide</li><li>cxlviii. Olodaterol, vilanterol and mometasone</li><li>cxlix. Olodaterol, vilanterol and fluticasone</li><li>cl. Olodaterol, vilanterol and budesonide</li><li>cli. Olodaterol, carmeterol and mometasone</li><li>clii. Olodaterol, carmeterol and fluticasone</li><li>cliii. Olodaterol, carmeterol and budesonide</li><li>cliv. Olodaterol, bambuterol and mometasone</li><li>clv. Olodaterol, bambuterol and fluticasone</li><li>clvi. Olodaterol, bambuterol and budesonide</li></ul>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0069" num="0069">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of;
<ul><li>i. Aclidinium, salbutamol and fluticasone</li><li>ii. Aclidinium, levosalbutamol and fluticasone</li><li>iii. Aclidinium, salbutamol and ciclesonide</li><li>iv. Aclidinium, levosalbutamol and ciclesonide</li><li>v. Aclidinium, salbutamol and budesonide</li><li>vi. Aclidinium, levosalbutamol and budesonide</li><li>vii. Aclidinium, salbutamol and mometasone</li><li>viii. Aclidinium, levosalbutamol and mometasone</li><li>ix. Aclidinium, salbutamol and beclometahsone</li><li>x. Aclidinium, levosalbutamol and beclometahsone</li><li>xi. Aclidinium, salbutamol and triamcinolone</li><li>xii. Aclidinium, levosalbutamol and triamcinolone</li><li>xiii. Aclidinium, salbutamol and flunisolide</li><li>xiv. Aclidinium, levosalbutamol and flunisolide</li><li>xv. Aclidinium, salbutamol and dexamethasone<!-- EPO <DP n="35"> --></li><li>xvi. Aclidinium, levosalbutamol and dexamethasone</li><li>xvii. Glycopyrronium, salbutamol and fluticasone</li><li>xviii. Glycopyrronium, levosalbutamol and fluticasone</li><li>xix. Glycopyrronium, salbutamol and ciclesonide</li><li>xx. Glycopyrronium, levosalbutamol and ciclesonide</li><li>xxi. Glycopyrronium, salbutamol and budesonide</li><li>xxii. Glycopyrronium, levosalbutamol and budesonide</li><li>xxiii. Glycopyrronium, salbutamol and mometasone</li><li>xxiv. Glycopyrronium, levosalbutamol and mometasone</li><li>xxv. Glycopyrronium, salbutamol and beclometahsone</li><li>xxvi. Glycopyrronium, levosalbutamol and beclometahsone</li><li>xxvii. Glycopyrronium, salbutamol and triamcinolone</li><li>xxviii. Glycopyrronium, levosalbutamol and triamcinolone</li><li>xxix. Glycopyrronium, salbutamol and flunisolide</li><li>xxx. Glycopyrronium, levosalbutamol and flunisolide</li><li>xxxi. Glycopyrronium, salbutamol and dexamethasone</li><li>xxxii. Glycopyrronium, levosalbutamol and dexamethasone</li><li>xxxiii. Daratropium, salbutamol and fluticasone</li><li>xxxiv. Daratropium, levosalbutamol and fluticasone</li><li>xxxv. Daratropium, salbutamol and ciclesonide</li><li>xxxvi. Daratropium, levosalbutamol and ciclesonide</li><li>xxxvii. Daratropium, salbutamol and budesonide</li><li>xxxviii. Daratropium, levosalbutamol and budesonide</li><li>xxxix. Daratropium, salbutamol and mometasone</li><li>xl. Daratropium, levosalbutamol and mometasone</li><li>xli. Daratropium, salbutamol and beclometahsone</li><li>xlii. Daratropium, levosalbutamol and beclometahsone</li><li>xliii. Daratropium, salbutamol and triamcinolone</li><li>xliv. Daratropium, levosalbutamol and triamcinolone</li><li>xlv. Daratropium, salbutamol and flunisolide</li><li>xlvi. Daratropium, levosalbutamol and flunisolide</li><li>xlvii. Daratropium, salbutamol and dexamethasone</li><li>xlviii. Daratropium, levosalbutamol and dexamethasone</li><li>xlix. Indacaterol, salbutamol and fluticasone</li><li>l. Indacaterol, levosalbutamol and fluticasone</li><li>li. Indacaterol, salbutamol and ciclesonide</li><li>lii. Indacaterol, levosalbutamol and ciclesonide<!-- EPO <DP n="36"> --></li><li>liii. Indacaterol, salbutamol and budesonide</li><li>liv. Indacaterol, levosalbutamol and budesonide</li><li>lv. Indacaterol, salbutamol and mometasone</li><li>lvi. Indacaterol, levosalbutamol and mometasone</li><li>lvii. Indacaterol, salbutamol and beclometahsone</li><li>lviii. Indacaterol, levosalbutamol and beclometahsone</li><li>lix. Indacaterol, salbutamol and triamcinolone</li><li>lx. Indacaterol, levosalbutamol and triamcinolone</li><li>lxi. Indacaterol, salbutamol and flunisolide</li><li>lxii. Indacaterol, levosalbutamol and flunisolide</li><li>lxiii. Indacaterol, salbutamol and dexamethasone</li><li>lxiv. Indacaterol, levosalbutamol and dexamethasone</li><li>lxv. Vilanterol, salbutamol and fluticasone</li><li>lxvi. Vilanterol, levosalbutamol and fluticasone</li><li>lxvii. Vilanterol, salbutamol and budesonide</li><li>lxviii. Vilanterol, levosalbutamol and budesonide</li><li>lxix. Vilanterol, salbutamol and ciclesonide</li><li>lxx. Vilanterol, levosalbutamol and ciclesonide</li><li>lxxi. Vilanterol, salbutamol and mometasone</li><li>lxxii. Vilanterol, levosalbutamol and mometasone</li><li>lxxiii. Vilanterol, salbutamol and beclomethasone</li><li>lxxiv. Vilanterol, levosalbutamol and beclomethasone</li><li>lxxv. Vilanterol, salbutamol and triamcinolone</li><li>lxxvi. Vilanterol, levosalbutamol and triamcinolone</li><li>lxxvii. Vilanterol, salbutamol and flunisolide</li><li>lxxviii. Vilanterol, levosalbutamol and flunisolide</li><li>lxxix. Vilanterol, salbutamol and dexamethasone</li><li>lxxx. Vilanterol, levosalbutamol and dexamethasone</li><li>lxxxi. Carmeterol, salbutamol and fluticasone</li><li>lxxxii. Carmeterol, levosalbutamol and fluticasone</li><li>lxxxiii. Carmeterol, salbutamol and ciclesonide</li><li>lxxxiv. Carmeterol, levosalbutamol and ciclesonide</li><li>lxxxv. Carmeterol, salbutamol and budesonide</li><li>lxxxvi. Carmeterol, levosalbutamol and budesonide</li><li>lxxxvii. Carmeterol, salbutamol and mometasone</li><li>lxxxviii. Carmeterol, levosalbutamol and mometasone</li><li>lxxxix. Carmeterol, salbutamol and beclomethasone<!-- EPO <DP n="37"> --></li><li>xc. Carmeterol, levosalbutamol and beclomethasone</li><li>xci. Carmeterol, salbutamol and triamcinolone</li><li>xcii. Carmeterol, levosalbutamol and triamcinolone</li><li>xciii. Carmeterol, salbutamol and flunisolide</li><li>xciv. Carmeterol, levosalbutamol and flunisolide</li><li>xcv. Carmeterol, salbutamol and dexamethasone</li><li>xcvi. Carmeterol, levosalbutamol and dexamethasone</li><li>xcvii. Olodaterol, salbutamol and fluticasone</li><li>xcviii. Olodaterol, levosalbutamol and fluticasone</li><li>xcix. Olodaterol, salbutamol and ciclesonide</li><li>c. Olodaterol, levosalbutamol and ciclesonide</li><li>ci. Olodaterol, salbutamol and budesonide</li><li>cii. Olodaterol, levosalbutamol and budesonide</li><li>ciii. Olodaterol, salbutamol and mometasone</li><li>civ. Olodaterol, levosalbutamol and mometasone</li><li>cv. Olodaterol, salbutamol and beclomethasone</li><li>cvi. Olodaterol, levosalbutamol and beclomethasone</li><li>cvii. Olodaterol, salbutamol and triamcinolone</li><li>cviii. Olodaterol, levosalbutamol and triamcinolone</li><li>cix. Olodaterol, salbutamol and flunisolide</li><li>cx. Olodaterol, levosalbutamol and flunisolide</li><li>cxi. Olodaterol, salbutamol and dexamethasone</li><li>cxii. Olodaterol, levosalbutamol and dexamethasone</li></ul>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0070" num="0070">According to another embodiment, the pharmaceutical compositions comprise any of the following combinations which are suitable for administration separately, sequentially or together in effective amounts of;
<ul><li>i. Formoterol, budesonide and tiotropium</li><li>ii. Salmeterol, fluticasone and tiotropium</li><li>iii. Carmoterol, tiotropium and fluticasone</li><li>iv. Salbutamol, formoterol and budesonide</li><li>v. Salbutamol, salmeterol and fluticasone</li><li>vi. Salbutamol, arformoterol and fluticasone</li></ul><!-- EPO <DP n="38"> -->
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</p><p id="p0071" num="0071">According to a preffered embodiment of the invention, the therapeutically effective amount of said pharmaceutical compositions are administered once a day and/ or administered twice a day.</p><p id="p0072" num="0072">According to a preffered embodiment, the pharmaceutical compositions are used for in the treatment of respiratory conditions selected from asthma and chronic obstructive pulmonary disease and other obstructive airways diseases. In particular, the combinations of compounds of the present invention are useful in the treatment of respiratory diseases and conditions comprising, asthma, acute respiratory distress syndrome, chronic pulmonary inflammatory disease, bronchitis, chronic bronchitis, chronic obstructive pulmonary (airway) disease, and silicosis; or immune diseases and conditions comprising: allergic rhinitis and chronic sinusitis.</p><p id="p0073" num="0073">According to a further embodiment, the pharmaceutical compositions are suitable for administarion separately, sequentially or together in effective amounts, together with a moisture tight and high barrier sealed blister or together with a capsule</p><p id="p0074" num="0074">In particular, the blister comprises aluminium to prevent ingress of moisture whereby the fine particle fraction (FPF) of the pharmaceutical composition dose is preserved. Furthermore, the blister is a high barrier sealed against moisture. Thus, the blister does not release any water to the dose and ingress of moisture from the exterior into the container is thereby prevented.</p><p id="p0075" num="0075">In a further preferred embodiment of the invention, the dry powder is in a capsule, which can be a pharmaceutically acceptable natural or synthetic polymer such as gelatin or hydroxypropyl methylcellulose.</p><p id="p0076" num="0076">In a preferred embodiment, the pharmaceutical compositions are suitable for administration separately, sequentially or together in effective amounts, together with an inhalation device. The device is preferably dry powder inhaler including the blister or the capsule described above.</p><p id="p0077" num="0077">In a further embodiment, the device in which the pharmaceutical composition is within the blister comprise at least one lock mechanism, enabling the device to remain<!-- EPO <DP n="39"> --> locked in both positions in which the device is ready for inhalation and the lid is in the closed position, and further enabling the device to setup again automatically, when the lid is closed.</p><p id="p0078" num="0078">In a further embodiment, the invention relates to a pharmaceutical kit comprising the drugs having amine and one or more additional active agents, in separate unit dosage forms, said forms being suitable for administration separately, sequentially or together in effective amounts, together with one or more inhalation devices for administration of drugs having amine and one or more additional active agents which are LAMAs, LABAs, SABAs and/or inhaled corticosteroids as described in detail above.</p><p id="p0079" num="0079">In a further embodiment, the process for making the pharmaceutical compositions for inhalation of the present invention comprises the following steps; To obtain a homogenous mixture first half of the coarse mannitol particules are added to a glass container later on fine mannitol particles are added and active ingredients are added to this mixture and blended in a turbula shaker. Then this mixture is elected. This election is not a milling, the aim of this election is to obtain a homogenous mixture. Then magnesium stearate and the rest of the coarse mannitol particels are added to this elected mixture during blending. Final powder mixture is furthermore blended and then filled into blisters or capsules.</p><p id="p0080" num="0080">This invention is further defined by reference to the following examples. In the following examples the drugs having amine has the ratio between the median particle size (d<sub>50</sub>) and d<sub>90</sub> is about 0.50. Although these examples are not intended to limit the scope of the present invention, it should be considered in the light of the description detailed above.</p><heading id="h0007"><b>Example - 1:</b></heading><p id="p0081" num="0081"><tables id="tabl0001" num="0001"><table frame="all"><title><b>Table 1</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>Magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="40"> --><tables id="tabl0002" num="0002"><table frame="none"><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="25mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="23mm"/><thead><row><entry namest="col1" nameend="col3" align="left" valign="top">Particle size of the drugs having amine (µm):</entry></row></thead><tbody><row><entry>d<sub>10</sub> : 0.10 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry/><entry/><entry/></row></tbody></tgroup><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="25mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="23mm"/><thead><row><entry namest="col1" nameend="col3" align="left" valign="top">Particle size of the fine mannitol (µm):</entry></row></thead><tbody><row><entry>d<sub>10</sub> : 1.0 - 4.0</entry><entry>d<sub>50</sub>: 4.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 15.0</entry></row><row><entry/><entry/><entry/></row></tbody></tgroup><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="25mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="23mm"/><thead><row><entry namest="col1" nameend="col3" align="left" valign="top">Particle size of the coarse mannitol (µm):</entry></row></thead><tbody><row><entry>d<sub>10</sub> : 10 - 50</entry><entry>d<sub>50</sub>: 50 - 75</entry><entry>d<sub>90</sub>: 75 - 250</entry></row><row><entry/><entry/><entry/></row></tbody></tgroup><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="25mm"/><colspec colnum="2" colname="col2" colwidth="22mm"/><colspec colnum="3" colname="col3" colwidth="23mm"/><thead><row><entry namest="col1" nameend="col3" align="left" valign="top">Particle size of the magnesium stearate (µm):</entry></row></thead><tbody><row><entry>d<sub>10</sub> : 0.25 - 2.5</entry><entry>d<sub>50</sub>: 3.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 20.0</entry></row></tbody></tgroup></table></tables></p><heading id="h0008"><b>Example</b> - <b>2:</b></heading><p id="p0082" num="0082"><tables id="tabl0003" num="0003"><table frame="all"><title><b>Table 2</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>LABAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>Magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables></p><heading id="h0009"><b>Particle size of ;</b></heading><p id="p0083" num="0083"><tables id="tabl0004" num="0004"><table frame="none"><tgroup cols="4" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="44mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="22mm"/><colspec colnum="4" colname="col4" colwidth="23mm"/><tbody><row><entry>LABAs (µm)</entry><entry>: d<sub>10</sub> : 0.10 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry>the drugs having amine (µm)</entry><entry>: d<sub>10</sub> : 0.10 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry>fine mannitol (µm)</entry><entry>: d<sub>10</sub> : 1.0 - 4.0</entry><entry>d<sub>50</sub>: 4.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 15.0</entry></row><row><entry>coarse mannitol (µm)</entry><entry>: d<sub>10</sub> : 10 - 50</entry><entry>d<sub>50</sub>: 50 - 75</entry><entry>d<sub>90</sub>: 75 - 250</entry></row><row><entry>magnesium stearate (µm)</entry><entry>: d<sub>10</sub> : 0.25 - 2.5</entry><entry>d<sub>50</sub>: 3.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 20.0</entry></row></tbody></tgroup></table></tables></p><heading id="h0010"><b>Examples</b> - <b>3:</b></heading><p id="p0084" num="0084"><tables id="tabl0005" num="0005"><table frame="all"><title><b>Table 3</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>LAMAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="41"> --></p><heading id="h0011"><b>Particle size of ;</b></heading><p id="p0085" num="0085"><tables id="tabl0006" num="0006"><table frame="none"><tgroup cols="4" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="44mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="22mm"/><colspec colnum="4" colname="col4" colwidth="23mm"/><tbody><row><entry>the drugs having amine (µm)</entry><entry>: d<sub>10</sub> : 0.10 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry>LAMAs(µm)</entry><entry>:d<sub>10</sub> : 0.10 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry>fine mannitol (µm)</entry><entry>: d<sub>10</sub> : 1.0 - 4.0</entry><entry>d<sub>50</sub>: 4.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 15.0</entry></row><row><entry>coarse mannitol (µm)</entry><entry>: d<sub>10</sub> : 10 - 50</entry><entry>d<sub>50</sub>: 50 -75</entry><entry>d<sub>90</sub>: 75 - 250</entry></row><row><entry>magnesium stearate (µm)</entry><entry>: d<sub>10</sub> : 0.25 - 2.5</entry><entry>d<sub>50</sub>: 3.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 20.0</entry></row></tbody></tgroup></table></tables></p><heading id="h0012"><b>Examples - 4:</b></heading><p id="p0086" num="0086"><tables id="tabl0007" num="0007"><table frame="all"><title><b>Table 4</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>SABAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables></p><heading id="h0013"><b>Particle size of;</b></heading><p id="p0087" num="0087"><tables id="tabl0008" num="0008"><table frame="none"><tgroup cols="4" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="44mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="22mm"/><colspec colnum="4" colname="col4" colwidth="23mm"/><tbody><row><entry>SABAs (µm)</entry><entry>: d<sub>10</sub> : 0.10 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry>the drugs having amine (µm)</entry><entry>: d<sub>10</sub> : 0.10 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry>fine mannitol (µm)</entry><entry>:d<sub>10</sub> : 1.0 - 4.0</entry><entry>d<sub>50</sub>: 4.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 15.0</entry></row><row><entry>coarse mannitol (µm)</entry><entry>: d<sub>10</sub> : 10 - 50</entry><entry>d<sub>50</sub>: 50 -75</entry><entry>d<sub>90</sub>: 75 - 250</entry></row><row><entry>magnesium stearate (µm)</entry><entry>: d<sub>10</sub> : 0.25 - 2.5</entry><entry>d<sub>50</sub>: 3.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 20.0</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="42"> --></p><heading id="h0014"><b>Examples</b> - <b>5:</b></heading><p id="p0088" num="0088"><tables id="tabl0009" num="0009"><table frame="all"><title><b>Table 5</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="35mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>Corticosteroids</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables></p><heading id="h0015"><b>Particle size of;</b></heading><p id="p0089" num="0089"><tables id="tabl0010" num="0010"><table frame="none"><tgroup cols="4" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="45mm"/><colspec colnum="2" colname="col2" colwidth="27mm"/><colspec colnum="3" colname="col3" colwidth="22mm"/><colspec colnum="4" colname="col4" colwidth="23mm"/><tbody><row><entry>Corticosteroids(µm)</entry><entry>: d<sub>10</sub> : 0.1 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry>the drugs having amine (µm)</entry><entry>: d<sub>10</sub> : 0.10 - 1.0</entry><entry>d<sub>50</sub>: 1.0 - 2.5</entry><entry>d<sub>90</sub>: 2.5 - 5.0</entry></row><row><entry>fine mannitol (µm)</entry><entry>: d<sub>10</sub> : 1.0 - 4.0</entry><entry>d<sub>50</sub>: 4.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 15.0</entry></row><row><entry>coarse mannitol (µm)</entry><entry>: d<sub>10</sub> : 10 - 50</entry><entry>d<sub>50</sub>: 50 - 75</entry><entry>d<sub>90</sub>: 75 - 250</entry></row><row><entry>magnesium stearate (µm)</entry><entry>: d<sub>10</sub> : 0.25 - 2.5</entry><entry>d<sub>50</sub>: 3.0 - 7.0</entry><entry>d<sub>90</sub>: 7.0 - 20.0</entry></row></tbody></tgroup></table></tables></p><heading id="h0016"><u><b>Examples</b> - <b>6:</b></u></heading><p id="p0090" num="0090">Particle size of each actives, mannitol and magnesium stearate are the same as above examples 1 to 5.
<tables id="tabl0011" num="0011"><table frame="all"><title>Table 6.1</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>LAMAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>LABAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="43"> -->
<tables id="tabl0012" num="0012"><table frame="all"><title><b>Table 6.2</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>LAMAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>SABAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0013" num="0013"><table frame="all"><title><b>Table 6.3</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>LAMAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>corticosteroids</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0014" num="0014"><table frame="all"><title><b>Table 6.4</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>LABAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>SABAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0015" num="0015"><table frame="all"><title><b>Table 6.5</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>LABAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>corticosteroids</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="44"> -->
<tables id="tabl0016" num="0016"><table frame="all"><title><b>Table 6.6</b></title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="29mm"/><thead><row><entry align="center" valign="top"><b>Ingredients</b></entry><entry align="center" valign="top"><b>Amount % (w/w)</b></entry></row></thead><tbody><row><entry>drugs having amine</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>SABAs</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>corticosteroids</entry><entry align="center">0.01 - 10.0</entry></row><row><entry>fine mannitol</entry><entry align="center">2.0 - 20.0</entry></row><row><entry>coarse mannitol</entry><entry align="center">20.0 - 98.0</entry></row><row><entry>magnesium stearate</entry><entry align="center">0.05 - 1.0</entry></row></tbody></tgroup></table></tables></p></description><claims mxw-id="PCLM56982643" lang="EN" load-source="patent-office"><!-- EPO <DP n="45"> --><claim id="c-en-0001" num="0001"><claim-text>A pharmaceutical composition for inhalation comprising separately, sequentially or together, drugs having amine in the form of a dry powder which are selected from a group consisting of aclidinium, glycopyrronium, daratropium, indacaterol, vilanterol, carmoterol or olodaterol or their pharmaceutically acceptable salt or ester, or in enantiomerically pure form or as a racemic mixture in admixture with a pharmaceutically acceptable carrier, other than lactose wherein pharmaceutically acceptable carrier is selected from a group consisting of mannitol, glucose, trehalose, cellobiose, sorbitol, maltitol or a combination of two or more of them and at least one ternary component.</claim-text></claim><claim id="c-en-0002" num="0002"><claim-text>The pharmaceutical composition according to claim 1, wherein the ternary component is selected from a group comprising magnesium stearate, stearic acid, sodium lauryl sulphate, sodium stearyl fumarate, stearyl alcohol and sodium benzoate or mixtures thereof.</claim-text></claim><claim id="c-en-0003" num="0003"><claim-text>The pharmaceutical composition according to claim 2, wherein the ternary component is magnesium stearate.</claim-text></claim><claim id="c-en-0004" num="0004"><claim-text>The pharmaceutical composition according to claim 3, wherein magnesium stearate is in an amount of 0.05 to 2.0% by weight, preferably in an amount of 0.1 to 1.0% by weight, more preferably in an amount of 0.15 to 0.5% by weight.</claim-text></claim><claim id="c-en-0005" num="0005"><claim-text>The pharmaceutical composition according to claim 3, wherein the particles of the magnesium stearate have a particle diameter of d<sub>10</sub> between 0.25 - 2.5 µm, d<sub>50</sub> between 3.0 - 7.0 µm and d<sub>90</sub> between 7.0 - 20.0 µm.</claim-text></claim><claim id="c-en-0006" num="0006"><claim-text>The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable carrier, other than lactose, comprise fine and coarse particles and the ratio between the fine particles to the coarse particles is between 0.01 - 0.25 by weight.</claim-text></claim><claim id="c-en-0007" num="0007"><claim-text>The pharmaceutical composition according to claim 1 and 6, wherein the fine particles of the said pharmaceutically acceptable carrier have a particle diameter of d<sub>10</sub> between 1.0 - 4.0 µm, d<sub>50</sub> between 4.0 - 7.0 µm and d<sub>90</sub> between 7.0 - 15.0 µm.</claim-text></claim><claim id="c-en-0008" num="0008"><claim-text>The pharmaceutical composition according to claim 1 and 6, wherein the coarse particles of the said pharmaceutically acceptable carrier have a particle diameter of d<sub>10</sub> between 10 - 50 µm, d<sub>50</sub> between 50 - 75 µm and d<sub>90</sub> between 75 - 250 µm.<!-- EPO <DP n="46"> --></claim-text></claim><claim id="c-en-0009" num="0009"><claim-text>The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable carrier is preferably mannitol.</claim-text></claim><claim id="c-en-0010" num="0010"><claim-text>The pharmaceutical composition according to claim 9, wherein the pharmaceutically acceptable carrier is optionally spray dried mannitol.</claim-text></claim><claim id="c-en-0011" num="0011"><claim-text>The pharmaceutical composition according to claim 1, wherein the average particle diameter (d<sub>50</sub>) of the drugs having amine is between 1.5 - 2.5 µm.</claim-text></claim><claim id="c-en-0012" num="0012"><claim-text>The pharmaceutical composition according to claim 1, further comprising one or more additional active agents selected from long acting muscarinic antagonists, long acting beta agonists, short acting beta-2 agonists, corticosteroids or a combination of two or more of them.</claim-text></claim><claim id="c-en-0013" num="0013"><claim-text>The pharmaceutical composition according to claim 12, wherein the long acting muscarinic antagonists are selected from the group comprising tiotropium, glycopyrronium, ipratropium, aclidinium, oxitropium or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture or a combination of two or more of them.</claim-text></claim><claim id="c-en-0014" num="0014"><claim-text>The pharmaceutical composition according to claim 12, wherein the long acting beta agonists are selected from the group comprising salmeterol, formoterol, arformoterol, indacaterol, olodaterol, vilanterol, carmoterol, bambuterol or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture or a combination of two or more of them.</claim-text></claim><claim id="c-en-0015" num="0015"><claim-text>The pharmaceutical composition according to claim 12, wherein the short acting beta-2 agonists are selected from the group comprising salbutamol, levosalbutamol, terbutaline, pirbuterol, procaterol, fenoterol, bitolterol, ritodrine, metaproterenol or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture or a combination of two or more of them.</claim-text></claim><claim id="c-en-0016" num="0016"><claim-text>The pharmaceutical composition according to claim 12, wherein the corticosteroids are selected from the group comprising fluticasone, ciclesonide, budesonide, mometasone, beclomethasone, triamcinolone, flunisolide, dexamethasone or a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture or a combination of two or more of them.<!-- EPO <DP n="47"> --></claim-text></claim><claim id="c-en-0017" num="0017"><claim-text>The pharmaceutical composition according to claim 12 and 13, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinium and tiotropium</claim-text>
<claim-text>ii. Aclidinium and glycopyrronium</claim-text>
<claim-text>iii. Aclidinum and ipratropium</claim-text>
<claim-text>iv. Aclidinum and oxitropium</claim-text>
<claim-text>v. Glycopyrronium and tiotropium</claim-text>
<claim-text>vi. Glycopyrronium and ipratropium</claim-text>
<claim-text>vii. Glycopyrronium and oxitropium</claim-text>
<claim-text>viii. Darotropium and tiotropium</claim-text>
<claim-text>ix. Darotropium and glycopyrronium</claim-text>
<claim-text>x. Darotropium and ipratropium</claim-text>
<claim-text>xi. Darotropium and aclidinium</claim-text>
<claim-text>xii. Darotropium and oxitropium</claim-text>
<claim-text>xiii. Indacaterol and tiotropium</claim-text>
<claim-text>xiv. Indacaterol and glycopyrronium</claim-text>
<claim-text>xv. Indacaterol and ipratropium</claim-text>
<claim-text>xvi. Indacaterol and aclidinium</claim-text>
<claim-text>xvii. Indacaterol and oxitropium</claim-text>
<claim-text>xviii. Vilanterol and tiotropium</claim-text>
<claim-text>xix. Vilanterol and glycopyrronium</claim-text>
<claim-text>xx. Vilanterol and ipratropium</claim-text>
<claim-text>xxi. Vilanterol and aclidinium</claim-text>
<claim-text>xxii. Vilanterol and oxitropium</claim-text>
<claim-text>xxiii. Carmoterol and tiotropium</claim-text>
<claim-text>xxiv. Carmoterol and glycopyrronium</claim-text>
<claim-text>xxv. Carmoterol and ipratropium</claim-text>
<claim-text>xxvi. Carmoterol and aclidinium</claim-text>
<claim-text>xxvii. Carmoterol and oxitropium</claim-text>
<claim-text>xxviii. Olodaterol and tiotropium</claim-text>
<claim-text>xxix. Olodaterol and ipratropium</claim-text>
<claim-text>xxx. Olodaterol and glycopyrronium</claim-text>
<claim-text>xxxi. Olodaterol and aclidinium</claim-text>
<claim-text>xxxii. Olodaterol and oxitropium<!-- EPO <DP n="48"> --> wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim-text></claim><claim id="c-en-0018" num="0018"><claim-text>The pharmaceutical composition according to claim 12 and 14, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinium and salmeterol</claim-text>
<claim-text>ii. Aclidinum and formoterol</claim-text>
<claim-text>iii. Aclidinium and arformoterol</claim-text>
<claim-text>iv. Aclidinium and indacaterol</claim-text>
<claim-text>v. Aclidinium and olodaterol</claim-text>
<claim-text>vi. Aclidinium and vilanterol</claim-text>
<claim-text>vii. Aclidinium and carmoterol</claim-text>
<claim-text>viii. Aclidinium and bambuterol</claim-text>
<claim-text>ix. Glycopyrronium and salmeterol</claim-text>
<claim-text>x. Glycopyrronium and formoterol</claim-text>
<claim-text>xi. Glycopyrronium and arformoterol</claim-text>
<claim-text>xii. Glycopyrronium and indacaterol</claim-text>
<claim-text>xiii. Glycopyrronium and olodaterol</claim-text>
<claim-text>xiv. Glycopyrronium and vilanterol</claim-text>
<claim-text>xv. Glycopyrronium and carmoterol</claim-text>
<claim-text>xvi. Glycopyrronium and bambuterol</claim-text>
<claim-text>xvii. Darotropium and salmeterol</claim-text>
<claim-text>xviii. Darotropium and formoterol</claim-text>
<claim-text>xix. Darotropium and arformoterol</claim-text>
<claim-text>xx. Darotropium and indacaterol</claim-text>
<claim-text>xxi. Darotropium and olodaterol</claim-text>
<claim-text>xxii. Darotropium and vilanterol</claim-text>
<claim-text>xxiii. Darotropium and carmoterol</claim-text>
<claim-text>xxiv. Darotropium and bambuterol</claim-text>
<claim-text>xxv. Indacaterol and salmeterol</claim-text>
<claim-text>xxvi. Indacaterol and formoterol</claim-text>
<claim-text>xxvii. Indacaterol and arformoterol</claim-text>
<claim-text>xxviii. Indacaterol and olodaterol</claim-text>
<claim-text>xxix. Indacaterol and vilanterol</claim-text>
<claim-text>xxx. Indacaterol and carmoterol<!-- EPO <DP n="49"> --></claim-text>
<claim-text>xxxi. Indacaterol and bambuterol</claim-text>
<claim-text>xxxii. Vilanterol and salmeterol</claim-text>
<claim-text>xxxiii. Vilanterol and formoterol</claim-text>
<claim-text>xxxiv. Vilanterol and arformoterol</claim-text>
<claim-text>xxxv. Vilanterol and olodaterol</claim-text>
<claim-text>xxxvi. Vilanterol and carmoterol</claim-text>
<claim-text>xxxvii. Vilanterol and bambuterol</claim-text>
<claim-text>xxxviii. Carmoterol and salmeterol</claim-text>
<claim-text>xxxix. Carmoterol and formoterol</claim-text>
<claim-text>xl. Carmoterol and arformoterol</claim-text>
<claim-text>xli. Carmoterol and olodaterol</claim-text>
<claim-text>xlii. Carmoterol and bambuterol</claim-text>
<claim-text>xliii. Olodaterol and salmeterol</claim-text>
<claim-text>xliv. Olodaterol and formoterol</claim-text>
<claim-text>xlv. Olodaterol and arformoterol</claim-text>
<claim-text>xlvi. Olodaterol and bambuterol</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0019" num="0019"><claim-text>The pharmaceutical composition according to claim 12 and 15, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinium and salbutamol</claim-text>
<claim-text>ii. Aclidinium and levosalbutamol</claim-text>
<claim-text>iii. Aclidinium and terbutaline</claim-text>
<claim-text>iv. Aclidinium and pirbuterol</claim-text>
<claim-text>v. Aclidinium and procaterol</claim-text>
<claim-text>vi. Aclidinium and fenoterol</claim-text>
<claim-text>vii. Aclidinium and bitolterol</claim-text>
<claim-text>viii. Aclidinium and ritodrine</claim-text>
<claim-text>ix. Aclidinium and metaproterenol</claim-text>
<claim-text>x. Glycopyrronium and salbutamol</claim-text>
<claim-text>xi. Glycopyrronium and levosalbutamol</claim-text>
<claim-text>xii. Glycopyrronium and terbutaline</claim-text>
<claim-text>xiii. Glycopyrronium and pirbuterol</claim-text>
<claim-text>xiv. Glycopyrronium and procaterol<!-- EPO <DP n="50"> --></claim-text>
<claim-text>xv. Glycopyrronium and fenoterol</claim-text>
<claim-text>xvi. Glycopyrronium and bitolterol</claim-text>
<claim-text>xvii. Glycopyrronium and ritodrine</claim-text>
<claim-text>xviii. Glycopyrronium and metaproterenol</claim-text>
<claim-text>xix. Darotropium and salbutamol</claim-text>
<claim-text>xx. Darotropium and levosalbutamol</claim-text>
<claim-text>xxi. Darotropium and terbutaline</claim-text>
<claim-text>xxii. Darotropium and pirbuterol</claim-text>
<claim-text>xxiii. Darotropium and procaterol</claim-text>
<claim-text>xxiv. Darotropium and fenoterol</claim-text>
<claim-text>xxv. Darotropium and bitolterol</claim-text>
<claim-text>xxvi. Darotropium and ritodrine</claim-text>
<claim-text>xxvii. Darotropium and metaproterenol</claim-text>
<claim-text>xxviii. Indacaterol and salbutamol</claim-text>
<claim-text>xxix. Indacaterol and levosalbutamol</claim-text>
<claim-text>xxx. Indacaterol and terbutaline</claim-text>
<claim-text>xxxi. Indacaterol and pirbuterol</claim-text>
<claim-text>xxxii. Indacaterol and procaterol</claim-text>
<claim-text>xxxiii. Indacaterol and fenoterol</claim-text>
<claim-text>xxxiv. Indacaterol and bitolterol</claim-text>
<claim-text>xxxv. Indacaterol and ritodrine</claim-text>
<claim-text>xxxvi. Indacaterol and metaproterenol</claim-text>
<claim-text>xxxvii. Vilanterol and salbutamol</claim-text>
<claim-text>xxxviii. Vilanterol and levosalbutamol</claim-text>
<claim-text>xxxix. Vilanterol and terbutaline</claim-text>
<claim-text>xl. Vilanterol and pirbuterol</claim-text>
<claim-text>xli. Vilanterol and procaterol</claim-text>
<claim-text>xlii. Vilanterol and fenoterol</claim-text>
<claim-text>xliii. Vilanterol and bitolterol</claim-text>
<claim-text>xliv. Vilanterol and ritodrine</claim-text>
<claim-text>xlv. Vilanterol and metaproterenol</claim-text>
<claim-text>xlvi. Carmoterol and salbutamol</claim-text>
<claim-text>xlvii. carmoterol and levosalbutamol</claim-text>
<claim-text>xlviii. carmoterol and terbutaline</claim-text>
<claim-text>xlix. carmoterol and pirbuterol</claim-text>
<claim-text>l. carmoterol and procaterol</claim-text>
<claim-text>li. carmoterol and fenoterol<!-- EPO <DP n="51"> --></claim-text>
<claim-text>lii. carmoterol and bitolterol</claim-text>
<claim-text>liii. carmoterol and ritodrine</claim-text>
<claim-text>liv. carmoterol and metaproterenol</claim-text>
<claim-text>lv. olodaterol and salbutamol</claim-text>
<claim-text>lvi. olodaterol and levosalbutamol</claim-text>
<claim-text>lvii. olodaterol and terbutaline</claim-text>
<claim-text>lviii. olodaterol and pirbuterol</claim-text>
<claim-text>lix. olodaterol and procaterol</claim-text>
<claim-text>lx. olodaterol and fenoterol</claim-text>
<claim-text>lxi. olodaterol and bitolterol</claim-text>
<claim-text>lxii. olodaterol and ritodrine</claim-text>
<claim-text>lxiii. olodaterol and metaproterenol</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0020" num="0020"><claim-text>The pharmaceutical composition according to claim 12 and 15, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinium and fluticasone</claim-text>
<claim-text>ii. Aclidinium and ciclesonide</claim-text>
<claim-text>iii. Aclidinium and budesonide</claim-text>
<claim-text>iv. Aclidinium and mometasone</claim-text>
<claim-text>v. Aclidinium and beclomethasone</claim-text>
<claim-text>vi. Aclidinium and triamcinolone</claim-text>
<claim-text>vii. Aclidinium and flunisolide</claim-text>
<claim-text>viii. Aclidinium and dexamethasone</claim-text>
<claim-text>ix. Glycopyrronium and fluticasone</claim-text>
<claim-text>x. Glycopyrronium and ciclesonide</claim-text>
<claim-text>xi. Glycopyrronium and budesonide</claim-text>
<claim-text>xii. Glycopyrronium and mometasone</claim-text>
<claim-text>xiii. Glycopyrronium and beclomethasone</claim-text>
<claim-text>xiv. Glycopyrronium and triamcinolone</claim-text>
<claim-text>xv. Glycopyrronium and flunisolide</claim-text>
<claim-text>xvi. Glycopyrronium and dexamethasone</claim-text>
<claim-text>xvii. Darotropium and fluticasone</claim-text>
<claim-text>xviii. Darotropium and ciclesonide<!-- EPO <DP n="52"> --></claim-text>
<claim-text>xix. Darotropium and budesonide</claim-text>
<claim-text>xx. Darotropium and mometasone</claim-text>
<claim-text>xxi. Darotropium and beclomethasone</claim-text>
<claim-text>xxii. Darotropium and triamcinolone</claim-text>
<claim-text>xxiii. Darotropium and flunisolide</claim-text>
<claim-text>xxiv. Darotropium and dexamethasone</claim-text>
<claim-text>xxv. Indacaterol and fluticasone</claim-text>
<claim-text>xxvi. Indacaterol and ciclesonide</claim-text>
<claim-text>xxvii. Indacaterol and budesonide</claim-text>
<claim-text>xxviii. Indacaterol and mometasone</claim-text>
<claim-text>xxix. Indacaterol and beclomethasone</claim-text>
<claim-text>xxx. Indacaterol and triamcinolone</claim-text>
<claim-text>xxxi. Indacaterol and flunisolide</claim-text>
<claim-text>xxxii. Indacaterol and dexamethasone</claim-text>
<claim-text>xxxiii. Vilanterol and fluticasone</claim-text>
<claim-text>xxxiv. Vilanterol and ciclesonide</claim-text>
<claim-text>xxxv. Vilanterol and budesonide</claim-text>
<claim-text>xxxvi. Vilanterol and mometasone</claim-text>
<claim-text>xxxvii. Vilanterol and beclomethasone</claim-text>
<claim-text>xxxviii. Vilanterol and triamcinolone</claim-text>
<claim-text>xxxix. Vilanterol and flunisolide</claim-text>
<claim-text>xl. Vilanterol and dexamethasone</claim-text>
<claim-text>xli. Carmoterol and fluticasone</claim-text>
<claim-text>xlii. Carmoterol and ciclesonide</claim-text>
<claim-text>xliii. Carmoterol and budesonide</claim-text>
<claim-text>xliv. Carmoterol and mometasone</claim-text>
<claim-text>xlv. Carmoterol and beclomethasone</claim-text>
<claim-text>xlvi. Carmoterol and triamcinolone</claim-text>
<claim-text>xlvii. Carmoterol and flunisolide</claim-text>
<claim-text>xlviii. Carmoterol and dexamethasone</claim-text>
<claim-text>xlix. Olodaterol and fluticasone</claim-text>
<claim-text>l. Olodaterol and ciclesonide</claim-text>
<claim-text>li. Olodaterol and budesonide</claim-text>
<claim-text>lii. Olodaterol and mometasone</claim-text>
<claim-text>liii. Olodaterol and beclamethasone</claim-text>
<claim-text>liv. Olodaterol and triamcinolone</claim-text>
<claim-text>lv. Olodaterol and flunisolide<!-- EPO <DP n="53"> --></claim-text>
<claim-text>lvi. Olodaterol and dexamethasone</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0021" num="0021"><claim-text>The pharmaceutical composition according to any preceding claims , comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinum, tiotropium and salmeterol</claim-text>
<claim-text>ii. Aclidinum, tiotropium and formoterol</claim-text>
<claim-text>iii. Aclidinum, tiotropium and arformoterol</claim-text>
<claim-text>iv. Aclidinum, tiotropium and indacaterol</claim-text>
<claim-text>v. Aclidinum, tiotropium and olodaterol</claim-text>
<claim-text>vi. Aclidinum, tiotropium and vilanterol</claim-text>
<claim-text>vii. Aclidinum, tiotropium and carmoterol</claim-text>
<claim-text>viii. Aclidinum, tiotropium and bambuterol</claim-text>
<claim-text>ix. Aclidinum, glycopyrronium and salmeterol</claim-text>
<claim-text>x. Aclidinum, glycopyrronium and formoterol</claim-text>
<claim-text>xi. Aclidinum, glycopyrronium and arformoterol</claim-text>
<claim-text>xii. Aclidinum, glycopyrronium and indacaterol</claim-text>
<claim-text>xiii. Aclidinum, glycopyrronium and olodaterol</claim-text>
<claim-text>xiv. Aclidinum, glycopyrronium and vilanterol</claim-text>
<claim-text>xv. Aclidinum, glycopyrronium and carmoterol</claim-text>
<claim-text>xvi. Aclidinum, glycopyrronium and bambuterol</claim-text>
<claim-text>xvii. Aclidinum, oxitropium and salmeterol</claim-text>
<claim-text>xviii. Aclidinum, oxitropium and formoterol</claim-text>
<claim-text>xix. Aclidinum, oxitropium and arformoterol</claim-text>
<claim-text>xx. Aclidinum, oxitropium and indacaterol</claim-text>
<claim-text>xxi. Aclidinum, oxitropium and olodaterol</claim-text>
<claim-text>xxii. Aclidinum, oxitropium and vilanterol</claim-text>
<claim-text>xxiii. Aclidinum, oxitropium and carmoterol</claim-text>
<claim-text>xxiv. Aclidinum, oxitropium and bambuterol</claim-text>
<claim-text>xxv. Glycopyrronium, tiotropium and salmeterol</claim-text>
<claim-text>xxvi. Glycopyrronium, tiotropium and formoterol</claim-text>
<claim-text>xxvii. Glycopyrronium, tiotropium and arformoterol</claim-text>
<claim-text>xxviii. Glycopyrronium, tiotropium and indacaterol</claim-text>
<claim-text>xxix. Glycopyrronium, tiotropium and olodaterol<!-- EPO <DP n="54"> --></claim-text>
<claim-text>xxx. Glycopyrronium, tiotropium and vilanterol</claim-text>
<claim-text>xxxi. Glycopyrronium, tiotropium and carmoterol</claim-text>
<claim-text>xxxii. Glycopyrronium, tiotropium and bambuterol</claim-text>
<claim-text>xxxiii. Glycopyrronium, oxitropium and salmeterol</claim-text>
<claim-text>xxxiv. Glycopyrronium, oxitropium and formoterol</claim-text>
<claim-text>xxxv. Glycopyrronium, oxitropium and arformoterol</claim-text>
<claim-text>xxxvi. Glycopyrronium, oxitropium and indacaterol</claim-text>
<claim-text>xxxvii. Glycopyrronium, oxitropium and olodaterol</claim-text>
<claim-text>xxxviii. Glycopyrronium, oxitropium and vilanterol</claim-text>
<claim-text>xxxix. Glycopyrronium, oxitropium and carmoterol</claim-text>
<claim-text>xl. Glycopyrronium, oxitropium and bambuterol</claim-text>
<claim-text>xli. Daratropium, tiotropium and salmeterol</claim-text>
<claim-text>xlii. Daratropium, tiotropium and formoterol</claim-text>
<claim-text>xliii. Daratropium, tiotropium and arformoterol</claim-text>
<claim-text>xliv. Daratropium, tiotropium and indacaterol</claim-text>
<claim-text>xlv. Daratropium, tiotropium and olodaterol</claim-text>
<claim-text>xlvi. Daratropium, tiotropium and vilanterol</claim-text>
<claim-text>xlvii. Daratropium, tiotropium and carmoterol</claim-text>
<claim-text>xlviii. Daratropium, tiotropium and bambuterol</claim-text>
<claim-text>xlix. Daratropium, glycopyrronium and salmeterol</claim-text>
<claim-text>l. Daratropium, glycopyrronium and formoterol</claim-text>
<claim-text>li. Daratropium, glycopyrronium and arformoterol</claim-text>
<claim-text>lii. Daratropium, glycopyrronium and indacaterol</claim-text>
<claim-text>liii. Daratropium, glycopyrronium and olodaterol</claim-text>
<claim-text>liv. Daratropium, glycopyrronium and vilanterol</claim-text>
<claim-text>lv. Daratropium, glycopyrronium and carmoterol</claim-text>
<claim-text>lvi. Daratropium, glycopyrronium and bambuterol</claim-text>
<claim-text>lvii. Daratropium, aclidinium and salmeterol</claim-text>
<claim-text>lviii. Daratropium, aclidinium and formoterol</claim-text>
<claim-text>lix. Daratropium, aclidinium and arformoterol</claim-text>
<claim-text>lx. Daratropium, aclidinium and indacaterol</claim-text>
<claim-text>lxi. Daratropium, aclidinium and olodaterol</claim-text>
<claim-text>lxii. Daratropium, aclidinium and vilanterol</claim-text>
<claim-text>lxiii. Daratropium, aclidinium and carmoterol</claim-text>
<claim-text>lxiv. Daratropium, aclidinium and bambuterol</claim-text>
<claim-text>lxv. Daratropium, oxitropium and salmeterol</claim-text>
<claim-text>lxvi. Daratropium, oxitropium and formoterol<!-- EPO <DP n="55"> --></claim-text>
<claim-text>lxvii. Daratropium, oxitropium and arformoterol</claim-text>
<claim-text>lxviii. Daratropium, oxitropium and indacaterol</claim-text>
<claim-text>lxix. Daratropium, oxitropium and olodaterol</claim-text>
<claim-text>lxx. Daratropium, oxitropium and vilanterol</claim-text>
<claim-text>lxxi. Daratropium, oxitropium and carmoterol</claim-text>
<claim-text>lxxii. Daratropium, oxitropium and bambuterol</claim-text>
<claim-text>lxxiii. Indacaterol, tiotropium and salmeterol</claim-text>
<claim-text>lxxiv. Indacaterol, tiotropium and formoterol</claim-text>
<claim-text>lxxv. Indacaterol, tiotropium and arformoterol</claim-text>
<claim-text>lxxvi. Indacaterol, tiotropium and olodaterol</claim-text>
<claim-text>lxxvii. Indacaterol, tiotropium and vilanterol</claim-text>
<claim-text>lxxviii. Indacaterol, tiotropium and carmoterol</claim-text>
<claim-text>lxxix. Indacaterol, tiotropium and bambuterol</claim-text>
<claim-text>lxxx. Indacaterol, glycopyrronium and salmeterol</claim-text>
<claim-text>lxxxi. Indacaterol, glycopyrronium and formoterol</claim-text>
<claim-text>lxxxii. Indacaterol, glycopyrronium and arformoterol</claim-text>
<claim-text>lxxxiii. Indacaterol, glycopyrronium and olodaterol</claim-text>
<claim-text>lxxxiv. Indacaterol, glycopyrronium and vilanterol</claim-text>
<claim-text>lxxxv. Indacaterol, glycopyrronium and carmoterol</claim-text>
<claim-text>lxxxvi. Indacaterol, glycopyrronium and bambuterol</claim-text>
<claim-text>lxxxvii. Indacaterol, aclidinium and salmeterol</claim-text>
<claim-text>lxxxviii. Indacaterol, aclidinium and formoterol</claim-text>
<claim-text>lxxxix. Indacaterol, aclidinium and arformoterol</claim-text>
<claim-text>xc. Indacaterol, aclidinium and olodaterol</claim-text>
<claim-text>xci. Indacaterol, aclidinium and vilanterol</claim-text>
<claim-text>xcii. Indacaterol, aclidinium and carmoterol</claim-text>
<claim-text>xciii. Indacaterol, aclidinium and bambuterol</claim-text>
<claim-text>xciv. Indacaterol, oxitropium and salmeterol</claim-text>
<claim-text>xcv. Indacaterol, oxitropium and formoterol</claim-text>
<claim-text>xcvi. Indacaterol, oxitropium and arformoterol</claim-text>
<claim-text>xcvii. Indacaterol, oxitropium and olodaterol</claim-text>
<claim-text>xcviii. Indacaterol, oxitropium and vilanterol</claim-text>
<claim-text>xcix. Indacaterol, oxitropium and carmoterol</claim-text>
<claim-text>c. Indacaterol, oxitropium and bambuterol</claim-text>
<claim-text>ci. Vilanterol, tiotropium and salmeterol</claim-text>
<claim-text>cii. Vilanterol, tiotropium and formoterol</claim-text>
<claim-text>ciii. Vilanterol, tiotropium and arformoterol<!-- EPO <DP n="56"> --></claim-text>
<claim-text>civ. Vilanterol, tiotropium and indacaterol</claim-text>
<claim-text>cv. Vilanterol, tiotropium and olodaterol</claim-text>
<claim-text>cvi. Vilanterol, tiotropium and carmoterol</claim-text>
<claim-text>cvii. Vilanterol, tiotropium and bambuterol</claim-text>
<claim-text>cviii. Vilanterol, glycopyrronium and salmeterol</claim-text>
<claim-text>cix. Vilanterol, glycopyrronium and formoterol</claim-text>
<claim-text>cx. Vilanterol, glycopyrronium and arformoterol</claim-text>
<claim-text>cxi. Vilanterol, glycopyrronium and indacaterol</claim-text>
<claim-text>cxii. Vilanterol, glycopyrronium and olodaterol</claim-text>
<claim-text>cxiii. Vilanterol, glycopyrronium and carmoterol</claim-text>
<claim-text>cxiv. Vilanterol, glycopyrronium and bambuterol</claim-text>
<claim-text>cxv. Vilanterol, aclidinium and salmeterol</claim-text>
<claim-text>cxvi. Vilanterol, aclidinium and formoterol</claim-text>
<claim-text>cxvii. Vilanterol, aclidinium and arformoterol</claim-text>
<claim-text>cxviii. Vilanterol, aclidinium and indacaterol</claim-text>
<claim-text>cxix. Vilanterol, aclidinium and olodaterol</claim-text>
<claim-text>cxx. Vilanterol, aclidinium and carmoterol</claim-text>
<claim-text>cxxi. Vilanterol, aclidinium and bambuterol</claim-text>
<claim-text>cxxii. Vilanterol, oxitropium and salmeterol</claim-text>
<claim-text>cxxiii. Vilanterol, oxitropium and formoterol</claim-text>
<claim-text>cxxiv. Vilanterol, oxitropium and arformoterol</claim-text>
<claim-text>cxxv. Vilanterol, oxitropium and indacaterol</claim-text>
<claim-text>cxxvi. Vilanterol, oxitropium and olodaterol</claim-text>
<claim-text>cxxvii. Vilanterol, oxitropium and carmoterol</claim-text>
<claim-text>cxxviii. Vilanterol, oxitropium and bambuterol</claim-text>
<claim-text>cxxix. Carmoterol, tiotropium and salmeterol</claim-text>
<claim-text>cxxx. Carmoterol, tiotropium and formoterol</claim-text>
<claim-text>cxxxi. Carmoterol, tiotropium and arformoterol</claim-text>
<claim-text>cxxxii. Carmoterol, tiotropium and indacaterol</claim-text>
<claim-text>cxxxiii. Carmoterol, tiotropium and olodaterol</claim-text>
<claim-text>cxxxiv. Carmoterol, tiotropium and vilanterol</claim-text>
<claim-text>cxxxv. Carmoterol, tiotropium and bambuterol</claim-text>
<claim-text>cxxxvi. Carmoterol, glycopyrronium and salmeterol</claim-text>
<claim-text>cxxxvii.Carmoterol, glycopyrronium and formoterol</claim-text>
<claim-text>cxxxviii. Carmoterol, glycopyrronium and arformoterol</claim-text>
<claim-text>cxxxix. Carmoterol, glycopyrronium and indacaterol</claim-text>
<claim-text>cxl. Carmoterol, glycopyrronium and olodaterol<!-- EPO <DP n="57"> --></claim-text>
<claim-text>cxli. Carmoterol, glycopyrronium and vilanterol</claim-text>
<claim-text>cxlii. Carmoterol, glycopyrronium and bambuterol</claim-text>
<claim-text>cxliii. Carmoterol, aclidinium and salmeterol</claim-text>
<claim-text>cxliv. Carmoterol, aclidinium and formoterol</claim-text>
<claim-text>cxlv. Carmoterol, aclidinium and arformoterol</claim-text>
<claim-text>cxlvi. Carmoterol, aclidinium and indacaterol</claim-text>
<claim-text>cxlvii. Carmoterol, aclidinium and olodaterol</claim-text>
<claim-text>cxlviii. Carmoterol, aclidinium and vilanterol</claim-text>
<claim-text>cxlix. Carmoterol, aclidinium and bambuterol</claim-text>
<claim-text>cl. Carmoterol, oxitropium and salmeterol</claim-text>
<claim-text>cli. Carmoterol, oxitropium and formoterol</claim-text>
<claim-text>clii. Carmoterol, oxitropium and arformoterol</claim-text>
<claim-text>cliii. Carmoterol, oxitropium and indacaterol</claim-text>
<claim-text>cliv. Carmoterol, oxitropium and olodaterol</claim-text>
<claim-text>clv. Carmoterol, oxitropium and vilanterol</claim-text>
<claim-text>clvi. Carmoterol, oxitropium and bambuterol</claim-text>
<claim-text>clvii. Olodaterol, tiotropium and salmeterol</claim-text>
<claim-text>clviii. Olodaterol, tiotropium and formoterol</claim-text>
<claim-text>clix. Olodaterol, tiotropium and arformoterol</claim-text>
<claim-text>clx. Olodaterol, tiotropium and indacaterol</claim-text>
<claim-text>clxi. Olodaterol, tiotropium and vilanterol</claim-text>
<claim-text>clxii. Olodaterol, tiotropium and bambuterol</claim-text>
<claim-text>clxiii. Olodaterol, glycopyrronium and salmeterol</claim-text>
<claim-text>clxiv. Olodaterol, glycopyrronium and formoterol</claim-text>
<claim-text>clxv. Olodaterol, glycopyrronium and arformoterol</claim-text>
<claim-text>clxvi. Olodaterol, glycopyrronium and indacaterol</claim-text>
<claim-text>clxvii. Olodaterol, glycopyrronium and vilanterol</claim-text>
<claim-text>clxviii. Olodaterol, glycopyrronium and bambuterol</claim-text>
<claim-text>clxix. Olodaterol, aclidinium and salmeterol</claim-text>
<claim-text>clxx. Olodaterol, aclidinium and formoterol</claim-text>
<claim-text>clxxi. Olodaterol, aclidinium and arformoterol</claim-text>
<claim-text>clxxii. Olodaterol, aclidinium and indacaterol</claim-text>
<claim-text>clxxiii. Olodaterol, aclidinium and vilanterol</claim-text>
<claim-text>clxxiv. Olodaterol, aclidinium and bambuterol</claim-text>
<claim-text>clxxv. Olodaterol, oxitropium and salmeterol</claim-text>
<claim-text>clxxvi. Olodaterol, oxitropium and formoterol</claim-text>
<claim-text>clxxvii. Olodaterol, oxitropium and arformoterol<!-- EPO <DP n="58"> --> clxxviii.Olodaterol, oxitropium and indacaterol</claim-text>
<claim-text>clxxix. Olodaterol, oxitropium and vilanterol</claim-text>
<claim-text>clxxx. Olodaterol, oxitropium and bambuterol</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0022" num="0022"><claim-text>The pharmaceutical composition according to any preceding claims, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinum, tiotropium and salbutamol</claim-text>
<claim-text>ii. Aclidinum, tiotropium and levosalbutamol</claim-text>
<claim-text>iii. Aclidinum, tiotropium and terbutaline</claim-text>
<claim-text>iv. Aclidinum, tiotropium and pirbutarol</claim-text>
<claim-text>v. Aclidinum, tiotropium and procaterol</claim-text>
<claim-text>vi. Aclidinum, tiotropium and fenoterol</claim-text>
<claim-text>vii. Aclidinum, tiotropium and ritodrine</claim-text>
<claim-text>viii. Aclidinum, tiotropium and bitolterol</claim-text>
<claim-text>ix. Aclidinum, tiotropium and metaproterenol</claim-text>
<claim-text>x. Aclidinum, glycopyrronium and salbutamol</claim-text>
<claim-text>xi. Aclidinum, glycopyrronium and levosalbutamol</claim-text>
<claim-text>xii. Aclidinum, glycopyrronium and terbutaline</claim-text>
<claim-text>xiii. Aclidinum, glycopyrronium and pirbuterol</claim-text>
<claim-text>xiv. Aclidinum, glycopyrronium and procaterol</claim-text>
<claim-text>xv. Aclidinum, glycopyrronium and fenoterol</claim-text>
<claim-text>xvi. Aclidinum, glycopyrronium and bitolterol</claim-text>
<claim-text>xvii. Aclidinum, glycopyrronium and ritodrine</claim-text>
<claim-text>xviii. Aclidinum, glycopyrronium and metaproterenol</claim-text>
<claim-text>xix. Aclidinum, ipratropium and salbutamol</claim-text>
<claim-text>xx. Aclidinum, ipratropium and levosalbutamol</claim-text>
<claim-text>xxi. Aclidinum, ipratropium and terbutaline</claim-text>
<claim-text>xxii. Aclidinum, ipratropium and pirbuterol</claim-text>
<claim-text>xxiii. Aclidinum, ipratropium and procaterol</claim-text>
<claim-text>xxiv. Aclidinum, ipratropium and fenoterol</claim-text>
<claim-text>xxv. Aclidinum, ipratropium and bitolterol</claim-text>
<claim-text>xxvi. Aclidinum, ipratropium and ritodrine</claim-text>
<claim-text>xxvii. Aclidinum, ipratropium and metaproterenol<!-- EPO <DP n="59"> --> xxviii. Aclidinum, oxitropium and salbutamol xxix. Aclidinum, oxitropium and levosalbutamol xxx. Aclidinum, oxitropium and terbutaline xxxi. Aclidinum, oxitropium and pirbuterol xxxii. Aclidinum, oxitropium and procaterol xxxiii. Aclidinum, oxitropium and fenoterol xxxiv. Aclidinum, oxitropium and bitolterol xxxv. Aclidinum, oxitropium and ritodrine xxxvi. Aclidinum, oxitropium and metaproterenol xxxvii. Glycopyrronium, tiotropium and salbutamol xxxviii. Glycopyrronium, tiotropium and levosalbutamol xxxix. Glycopyrronium, tiotropium and terbutaline xl. Glycopyrronium, tiotropium and pirbuterol xli. Glycopyrronium, tiotropium and procaterol xlii. Glycopyrronium, tiotropium and fenoterol xliii. Glycopyrronium, tiotropium and bitolterol xliv. Glycopyrronium, tiotropium and ritodrine xlv. Glycopyrronium, tiotropium and metaproterenol xlvi. Glycopyrronium, ipratropium and salbutamol xlvii. Glycopyrronium, ipratropium and levosalbutamol xlviii. Glycopyrronium, ipratropium and terbutaline xlix. Glycopyrronium, ipratropium and pirbuterol l. Glycopyrronium, ipratropium and procaterol li. Glycopyrronium, ipratropium and fenoterol lii. Glycopyrronium, ipratropium and bitolterol liii. Glycopyrronium, ipratropium and ritodrine liv. Glycopyrronium, ipratropium and metaproterenol lv. Glycopyrronium, oxitropium and salbutamol lvi. Glycopyrronium, oxitropium and levosalbutamol lvii. Glycopyrronium, oxitropium and terbutaline lviii. Glycopyrronium, oxitropium and pirbuterol lix. Glycopyrronium, oxitropium and procaterol lx. Glycopyrronium, oxitropium and fenoterol lxi. Glycopyrronium, oxitropium and bitolterol lxii. Glycopyrronium, oxitropium and ritodrine lxiii. Glycopyrronium, oxitropium and metaproterenol lxiv. Daratropium, tiotropium and salbutamol<!-- EPO <DP n="60"> --></claim-text>
<claim-text>lxv. Daratropium, tiotropium and levosalbutamol</claim-text>
<claim-text>lxvi. Daratropium, tiotropium and terbutaline</claim-text>
<claim-text>lxvii. Daratropium, tiotropium and pirbuterol</claim-text>
<claim-text>lxviii. Daratropium, tiotropium and procaterol</claim-text>
<claim-text>lxix. Daratropium, tiotropium and fenoterol</claim-text>
<claim-text>lxx. Daratropium, tiotropium and bitolterol</claim-text>
<claim-text>lxxi. Daratropium, tiotropium and ritodrine</claim-text>
<claim-text>lxxii. Daratropium, tiotropium and metaproterenol</claim-text>
<claim-text>lxxiii. Daratropium, aclidinium and salbutamol</claim-text>
<claim-text>lxxiv. Daratropium, aclidinium and levosalbutamol</claim-text>
<claim-text>lxxv. Daratropium, aclidinium and terbutaline</claim-text>
<claim-text>lxxvi. Daratropium, aclidinium and pirbuterol</claim-text>
<claim-text>lxxvii. Daratropium, aclidinium and procaterol</claim-text>
<claim-text>lxxviii. Daratropium, aclidinium and fenoterol</claim-text>
<claim-text>lxxix. Daratropium, aclidinium and bitolterol</claim-text>
<claim-text>lxxx. Daratropium, aclidinium and ritodrine</claim-text>
<claim-text>lxxxi. Daratropium, aclidinium and metaproterenol</claim-text>
<claim-text>lxxxii. Daratropium, glycopyrronium and salbutamol</claim-text>
<claim-text>lxxxiii. Daratropium, glycopyrronium and levosalbutamol</claim-text>
<claim-text>lxxxiv. Daratropium, glycopyrronium and terbutaline</claim-text>
<claim-text>lxxxv. Daratropium, glycopyrronium and pirbuterol</claim-text>
<claim-text>lxxxvi. Daratropium, glycopyrronium and procaterol</claim-text>
<claim-text>lxxxvii. Daratropium, glycopyrronium and fenoterol</claim-text>
<claim-text>lxxxviii. Daratropium, glycopyrronium and bitolterol</claim-text>
<claim-text>lxxxix. Daratropium, glycopyrronium and ritodrine</claim-text>
<claim-text>xc. Daratropium, glycopyrronium and metaproterenol</claim-text>
<claim-text>xci. Daratropium, ipratropium and salbutamol</claim-text>
<claim-text>xcii. Daratropium, ipratropium and levosalbutamol</claim-text>
<claim-text>xciii. Daratropium, ipratropium and terbutaline</claim-text>
<claim-text>xciv. Daratropium, ipratropium and pirbuterol</claim-text>
<claim-text>xcv. Daratropium, ipratropium and procaterol</claim-text>
<claim-text>xcvi. Daratropium, ipratropium and fenoterol</claim-text>
<claim-text>xcvii. Daratropium, ipratropium and bitolterol</claim-text>
<claim-text>xcviii. Daratropium, ipratropium and ritodrine</claim-text>
<claim-text>xcix. Daratropium, ipratropium and metaproterenol</claim-text>
<claim-text>c. Daratropium, oxitropium and salbutamol</claim-text>
<claim-text>ci. Daratropium, oxitropium and levosalbutamol<!-- EPO <DP n="61"> --></claim-text>
<claim-text>cii. Daratropium, oxitropium and terbutaline</claim-text>
<claim-text>ciii. Daratropium, oxitropium and pirbuterol</claim-text>
<claim-text>civ. Daratropium, oxitropium and procaterol</claim-text>
<claim-text>cv. Daratropium, oxitropium and fenoterol</claim-text>
<claim-text>cvi. Daratropium, oxitropium and bitolterol</claim-text>
<claim-text>cvii. Daratropium, oxitropium and ritodrine</claim-text>
<claim-text>cviii. Daratropium, oxitropium and metaproterenol</claim-text>
<claim-text>cix. Indacaterol, tirotropium and salbutamol</claim-text>
<claim-text>cx. Indacaterol, tirotropium and levosalbutamol</claim-text>
<claim-text>cxi. Indacaterol, tirotropium and terbutaline</claim-text>
<claim-text>cxii. Indacaterol, tirotropium and pirbuterol</claim-text>
<claim-text>cxiii. Indacaterol, tirotropium and procaterol</claim-text>
<claim-text>cxiv. Indacaterol, tirotropium and fenoterol</claim-text>
<claim-text>cxv. Indacaterol, tirotropium and bitolterol</claim-text>
<claim-text>cxvi. Indacaterol, tirotropium and ritodrine</claim-text>
<claim-text>cxvii. Indacaterol, tirotropium and metaproterenol</claim-text>
<claim-text>cxviii. Indacaterol, glycopyrronium and salbutamol</claim-text>
<claim-text>cxix. Indacaterol, glycopyrronium and levosalbutamol</claim-text>
<claim-text>cxx. Indacaterol, glycopyrronium and terbutaline</claim-text>
<claim-text>cxxi. Indacaterol, glycopyrronium and pirbuterol</claim-text>
<claim-text>cxxii. Indacaterol, glycopyrronium and procaterol</claim-text>
<claim-text>cxxiii. Indacaterol, glycopyrronium and fenoterol</claim-text>
<claim-text>cxxiv. Indacaterol, glycopyrronium and bitolterol</claim-text>
<claim-text>cxxv. Indacaterol, glycopyrronium and ritodrine</claim-text>
<claim-text>cxxvi. Indacaterol, glycopyrronium and metaproterenol</claim-text>
<claim-text>cxxvii. Indacaterol, aclidinium and salbutamol</claim-text>
<claim-text>cxxviii. Indacaterol, aclidinium and levosalbutamol</claim-text>
<claim-text>cxxix. Indacaterol, aclidinium and terbutaline</claim-text>
<claim-text>cxxx. Indacaterol, aclidinium and pirbuterol</claim-text>
<claim-text>cxxxi. Indacaterol, aclidinium and procaterol</claim-text>
<claim-text>cxxxii. Indacaterol, aclidinium and fenoterol</claim-text>
<claim-text>cxxxiii. Indacaterol, aclidinium and bitolterol</claim-text>
<claim-text>cxxxiv. Indacaterol, aclidinium and ritodrine</claim-text>
<claim-text>cxxxv. Indacaterol, aclidinium and metaproterenol</claim-text>
<claim-text>cxxxvi. Indacaterol, ipratropium and salbutamol</claim-text>
<claim-text>cxxxvii. Indacaterol, ipratropium and levosalbutamol</claim-text>
<claim-text>cxxxviii. Indacaterol, ipratropium and terbutaline<!-- EPO <DP n="62"> --></claim-text>
<claim-text>cxxxix. Indacaterol, ipratropium and pirbuterol</claim-text>
<claim-text>cxl. Indacaterol, ipratropium and procaterol</claim-text>
<claim-text>cxli. Indacaterol, ipratropium and fenoterol</claim-text>
<claim-text>cxlii. Indacaterol, ipratropium and bitolterol</claim-text>
<claim-text>cxliii. Indacaterol, ipratropium and ritodrine</claim-text>
<claim-text>cxliv. Indacaterol, ipratropium and metaproterenol</claim-text>
<claim-text>cxlv. Indacaterol, oxitropium and salbutamol</claim-text>
<claim-text>cxlvi. Indacaterol, oxitropium and levosalbutamol</claim-text>
<claim-text>cxlvii. Indacaterol, oxitropium and terbutaline</claim-text>
<claim-text>cxlviii. Indacaterol, oxitropium and pirbuterol</claim-text>
<claim-text>cxlix. Indacaterol, oxitropium and procaterol</claim-text>
<claim-text>cl. Indacaterol, oxitropium and fenoterol</claim-text>
<claim-text>cli. Indacaterol, oxitropium and bitolterol</claim-text>
<claim-text>clii. Indacaterol, oxitropium and ritodrine</claim-text>
<claim-text>cliii. Indacaterol, oxitropium and metaproterenol</claim-text>
<claim-text>cliv. Vilanterol, tiotropium and salbutamol</claim-text>
<claim-text>clv. Vilanterol, tiotropium and levosalbutamol</claim-text>
<claim-text>clvi. Vilanterol, tiotropium and terbutaline</claim-text>
<claim-text>clvii. Vilanterol, tiotropium and pirbuterol</claim-text>
<claim-text>clviii. Vilanterol, tiotropium and procaterol</claim-text>
<claim-text>clix. Vilanterol, tiotropium and fenoterol</claim-text>
<claim-text>clx. Vilanterol, tiotropium and bitolterol</claim-text>
<claim-text>clxi. Vilanterol, tiotropium and ritodrine</claim-text>
<claim-text>clxii. Vilanterol, tiotropium and metaproterenol</claim-text>
<claim-text>clxiii. Vilanterol, glycopyrronium and salbutamol</claim-text>
<claim-text>clxiv. Vilanterol, glycopyrronium and levosalbutamol</claim-text>
<claim-text>clxv. Vilanterol, glycopyrronium and terbutaline</claim-text>
<claim-text>clxvi. Vilanterol, glycopyrronium and pirbuterol</claim-text>
<claim-text>clxvii. Vilanterol, glycopyrronium and procaterol</claim-text>
<claim-text>clxviii. Vilanterol, glycopyrronium and fenoterol</claim-text>
<claim-text>clxix. Vilanterol, glycopyrronium and bitolterol</claim-text>
<claim-text>clxx. Vilanterol, glycopyrronium and ritodrine</claim-text>
<claim-text>clxxi. Vilanterol, glycopyrronium and metaproterenol</claim-text>
<claim-text>clxxii. Vilanterol, ipratropium and salbutamol</claim-text>
<claim-text>clxxiii. Vilanterol, ipratropium and levosalbutamol</claim-text>
<claim-text>clxxiv. Vilanterol, ipratropium and terbutaline</claim-text>
<claim-text>clxxv. Vilanterol, ipratropium and pirbuterol<!-- EPO <DP n="63"> --></claim-text>
<claim-text>clxxvi. Vilanterol, ipratropium and procaterol</claim-text>
<claim-text>clxxvii. Vilanterol, ipratropium and fenoterol</claim-text>
<claim-text>clxxviii. Vilanterol, ipratropium and bitolterol</claim-text>
<claim-text>clxxix. Vilanterol, ipratropium and ritodrine</claim-text>
<claim-text>clxxx. Vilanterol, ipratropium and metaproterenol</claim-text>
<claim-text>clxxxi. Vilanterol, aclidinium and salbutamol</claim-text>
<claim-text>clxxxii. Vilanterol, aclidinium and levosalbutamol</claim-text>
<claim-text>clxxxiii. Vilanterol, aclidinium and terbutaline</claim-text>
<claim-text>clxxxiv.Vilanterol, aclidinium and pirbuterol</claim-text>
<claim-text>clxxxv. Vilanterol, aclidinium and procaterol</claim-text>
<claim-text>clxxxvi. Vilanterol, aclidinium and fenoterol</claim-text>
<claim-text>clxxxvii. Vilanterol, aclidinium and bitolterol</claim-text>
<claim-text>clxxxviii. Vilanterol, aclidinium and ritodrine</claim-text>
<claim-text>clxxxix. Vilanterol, aclidinium and metaproterenol</claim-text>
<claim-text>cxc. Vilanterol, oxitropium and salbutamol</claim-text>
<claim-text>cxci. Vilanterol, oxitropium and levosalbutamol</claim-text>
<claim-text>cxcii. Vilanterol, oxitropium and terbutaline</claim-text>
<claim-text>cxciii. Vilanterol, oxitropium and pirbuterol</claim-text>
<claim-text>cxciv. Vilanterol, oxitropium and procaterol</claim-text>
<claim-text>cxcv. Vilanterol, oxitropium and fenoterol</claim-text>
<claim-text>cxcvi. Vilanterol, oxitropium and bitolterol</claim-text>
<claim-text>cxcvii. Vilanterol, oxitropium and ritodrine</claim-text>
<claim-text>cxcviii. Vilanterol, oxitropium and metaproterenol</claim-text>
<claim-text>cxcix. Carmoterol, tiotropium and salbutamol</claim-text>
<claim-text>cc. Carmoterol, tiotropium and levosalbutamol</claim-text>
<claim-text>cci. Carmoterol, tiotropium and terbutaline</claim-text>
<claim-text>ccii. Carmoterol, tiotropium and pirbuterol</claim-text>
<claim-text>cciii. Carmoterol, tiotropium and procaterol</claim-text>
<claim-text>cciv. Carmoterol, tiotropium and fenoterol</claim-text>
<claim-text>ccv. Carmoterol, tiotropium and bitolterol</claim-text>
<claim-text>ccvi. Carmoterol, tiotropium and ritodrine</claim-text>
<claim-text>ccvii. Carmoterol, tiotropium and metaproterenol</claim-text>
<claim-text>ccviii. Carmoterol, ipratropium and levosalbutamol</claim-text>
<claim-text>ccix. Carmoterol, ipratropium and salbutamol</claim-text>
<claim-text>ccx. Carmoterol, ipratropium and terbutaline</claim-text>
<claim-text>ccxi. Carmoterol, ipratropium and pirbuterol</claim-text>
<claim-text>ccxii. Carmoterol, ipratropium and procaterol<!-- EPO <DP n="64"> --></claim-text>
<claim-text>ccxiii. Carmoterol, ipratropium and fenoterol</claim-text>
<claim-text>ccxiv. Carmoterol, ipratropium and bitolterol</claim-text>
<claim-text>ccxv. Carmoterol, ipratropium and ritodrine</claim-text>
<claim-text>ccxvi. Carmoterol, ipratropium and metaproterenol</claim-text>
<claim-text>ccxvii. Carmoterol, aclidinum and levosalbutamol</claim-text>
<claim-text>ccxviii. Carmoterol, aclidinum and salbutamol</claim-text>
<claim-text>ccxix. Carmoterol, aclidinum and terbutaline</claim-text>
<claim-text>ccxx. Carmoterol, aclidinum and pirbuterol</claim-text>
<claim-text>ccxxi. Carmoterol, aclidinum and procaterol</claim-text>
<claim-text>ccxxii. Carmoterol, aclidinum and fenoterol</claim-text>
<claim-text>ccxxiii. Carmoterol, aclidinum and bitolterol</claim-text>
<claim-text>ccxxiv. Carmoterol, aclidinum and ritodrine</claim-text>
<claim-text>ccxxv. Carmoterol, aclidinum and metaproterenol</claim-text>
<claim-text>ccxxvi. Carmoterol, oxitropium and salbutamol</claim-text>
<claim-text>ccxxvii.Carmoterol, oxitropium and levosalbutamol</claim-text>
<claim-text>ccxxviii. Carmoterol, oxitropium and terbutaline</claim-text>
<claim-text>ccxxix. Carmoterol, oxitropium and pirbuterol</claim-text>
<claim-text>ccxxx. Carmoterol, oxitropium and procaterol</claim-text>
<claim-text>ccxxxi. Carmoterol, oxitropium and fenoterol</claim-text>
<claim-text>ccxxxii.Carmoterol, oxitropium and bitolterol</claim-text>
<claim-text>ccxxxiii. Carmoterol, oxitropium and ritodrine</claim-text>
<claim-text>ccxxxiv. Carmoterol, oxitropium and metaproterenol</claim-text>
<claim-text>ccxxxv. Olodaterol, tiotropium and salbutamol</claim-text>
<claim-text>ccxxxvi. Olodaterol, tiotropium and levosalbutamol</claim-text>
<claim-text>ccxxxvii. Olodaterol, tiotropium and terbutaline</claim-text>
<claim-text>ccxxxviii. Olodaterol, tiotropium and pirbuterol</claim-text>
<claim-text>ccxxxix. Olodaterol, tiotropium and procaterol</claim-text>
<claim-text>ccxl. Olodaterol, tiotropium and fenoterol</claim-text>
<claim-text>ccxli. Olodaterol, tiotropium and bitolterol</claim-text>
<claim-text>ccxlii. Olodaterol, tiotropium and ritodrine</claim-text>
<claim-text>ccxliii. Olodaterol, tiotropium and metaproterenol</claim-text>
<claim-text>ccxliv. Olodaterol, ipratropium and salbutamol</claim-text>
<claim-text>ccxlv. Olodaterol, ipratropium and levosalbutamol</claim-text>
<claim-text>ccxlvi. Olodaterol, ipratropium and terbutaline</claim-text>
<claim-text>ccxlvii. Olodaterol, ipratropium and pirbuterol</claim-text>
<claim-text>ccxlviii.Olodaterol, ipratropium and procaterol</claim-text>
<claim-text>ccxlix. Olodaterol, ipratropium and fenoterol<!-- EPO <DP n="65"> --> ccl. Olodaterol, ipratropium and bitolterol</claim-text>
<claim-text>ccli. Olodaterol, ipratropium and ritodrine</claim-text>
<claim-text>cclii. Olodaterol, ipratropium and metaproterenol</claim-text>
<claim-text>ccliii. Olodaterol, aclidinum and salbutamol</claim-text>
<claim-text>ccliv. Olodaterol, aclidinum and levosalbutamol</claim-text>
<claim-text>cclv. Olodaterol, aclidinum and terbutaline</claim-text>
<claim-text>cclvi. Olodaterol, aclidinum and pirbuterol</claim-text>
<claim-text>cclvii. Olodaterol, aclidinum and procaterol</claim-text>
<claim-text>cclviii. Olodaterol, aclidinum and fenoterol</claim-text>
<claim-text>cclix. Olodaterol, aclidinum and bitolterol</claim-text>
<claim-text>cclx. Olodaterol, aclidinum and ritodrine</claim-text>
<claim-text>cclxi. Olodaterol, aclidinum and metaproterenol</claim-text>
<claim-text>cclxii. Olodaterol, glycopyrronium and salbutamol</claim-text>
<claim-text>cclxiii. Olodaterol, glycopyrronium and levosalbutamol</claim-text>
<claim-text>cclxiv. Olodaterol, glycopyrronium and terbutaline</claim-text>
<claim-text>cclxv. Olodaterol, glycopyrronium and pirbuterol</claim-text>
<claim-text>cclxvi. Olodaterol, glycopyrronium and procaterol</claim-text>
<claim-text>cclxvii. Olodaterol, glycopyrronium and fenoterol</claim-text>
<claim-text>cclxviii. Olodaterol, glycopyrronium and bitolterol</claim-text>
<claim-text>cclxix. Olodaterol, glycopyrronium and ritodrine</claim-text>
<claim-text>cclxx. Olodaterol, glycopyrronium and metaproterenol</claim-text>
<claim-text>cclxxi. Olodaterol, oxitropium and salbutamol</claim-text>
<claim-text>cclxxii. Olodaterol, oxitropium and levosalbutamol</claim-text>
<claim-text>cclxxiii. Olodaterol, oxitropium and terbutaline</claim-text>
<claim-text>cclxxiv. Olodaterol, oxitropium and pirbuterol</claim-text>
<claim-text>cclxxv. Olodaterol, oxitropium and procaterol</claim-text>
<claim-text>cclxxvi. Olodaterol, oxitropium and fenoterol</claim-text>
<claim-text>cclxxvii. Olodaterol, oxitropium and bitolterol</claim-text>
<claim-text>cclxxviii. Olodaterol, oxitropium and ritodrine</claim-text>
<claim-text>cclxxix. Olodaterol, oxitropium and metaproterenol</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0023" num="0023"><claim-text>The pharmaceutical composition according to any preceding claims, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;<!-- EPO <DP n="66"> -->
<claim-text>i. Aclidinum, tiotropium and fluticasone</claim-text>
<claim-text>ii. Aclidinum, tiotropium and ciclesonide</claim-text>
<claim-text>iii. Aclidinum, tiotropium and budesonide</claim-text>
<claim-text>iv. Aclidinum, tiotropium and mometasone</claim-text>
<claim-text>v. Aclidinum, tiotropium and beclomethasone</claim-text>
<claim-text>vi. Aclidinum, tiotropium and triamcinolone</claim-text>
<claim-text>vii. Aclidinum, tiotropium and flunisolide</claim-text>
<claim-text>viii. Aclidinum, tiotropium and dexomethasone</claim-text>
<claim-text>ix. Daratropium, tiotropium and fluticasone</claim-text>
<claim-text>x. Daratropium, tiotropium and ciclesonide</claim-text>
<claim-text>xi. Daratropium, tiotropium and budesonide</claim-text>
<claim-text>xii. Daratropium, tiotropium and mometasone</claim-text>
<claim-text>xiii. Daratropium, tiotropium and beclamethasone</claim-text>
<claim-text>xiv. Daratropium, tiotropium and triamcinolone</claim-text>
<claim-text>xv. Daratropium, tiotropium and flunisolide</claim-text>
<claim-text>xvi. Daratropium, tiotropium and dexomethasone</claim-text>
<claim-text>xvii. Indacaterol, tiotropium and fluticasone</claim-text>
<claim-text>xviii. Indacaterol, tiotropium and budesonide</claim-text>
<claim-text>xix. Indacaterol, tiotropium and ciclesonide</claim-text>
<claim-text>xx. Indacaterol, tiotropium and mometasone</claim-text>
<claim-text>xxi. Indacaterol, tiotropium and beclamethasone</claim-text>
<claim-text>xxii. Indacaterol, tiotropium and triamcinolone</claim-text>
<claim-text>xxiii. Indacaterol, tiotropium and flunisolide</claim-text>
<claim-text>xxiv. Indacaterol, tiotropium and dexomethasone</claim-text>
<claim-text>xxv. Vilanterol, tiotropium and ciclesonide</claim-text>
<claim-text>xxvi. vilanterol, tiotropium and fluticasone</claim-text>
<claim-text>xxvii. vilanterol, tiotropium and budesonide</claim-text>
<claim-text>xxviii. vilanterol, tiotropium and mometasone</claim-text>
<claim-text>xxix. vilanterol, tiotropium and beclamethasone</claim-text>
<claim-text>xxx. vilanterol, tiotropium and triamcinolone</claim-text>
<claim-text>xxxi. vilanterol, tiotropium and flunisolide</claim-text>
<claim-text>xxxii. vilanterol, tiotropium and dexomethasone</claim-text>
<claim-text>xxxiii. carmoterol, tiotropium and budesonide</claim-text>
<claim-text>xxxiv. carmoterol, tiotropium and ciclesonide</claim-text>
<claim-text>xxxv. carmoterol, tiotropium and fluticasone</claim-text>
<claim-text>xxxvi. carmoterol, tiotropium and mometasone</claim-text>
<claim-text>xxxvii. carmoterol, tiotropium and beclamethasone<!-- EPO <DP n="67"> --></claim-text>
<claim-text>xxxviii. carmoterol, tiotropium and triamcinolone</claim-text>
<claim-text>xxxix. carmoterol, tiotropium and flunisolide</claim-text>
<claim-text>xl. carmoterol, tiotropium and dexomethasone</claim-text>
<claim-text>xli. Olodaterol, tiotropium and ciclesonide</claim-text>
<claim-text>xlii. Olodaterol, tiotropium and fluticasone</claim-text>
<claim-text>xliii. Olodaterol, tiotropium and budesonide</claim-text>
<claim-text>xliv. Olodaterol, tiotropium and mometasone</claim-text>
<claim-text>xlv. Olodaterol, tiotropium and beclamethasone</claim-text>
<claim-text>xlvi. Olodaterol, tiotropium and triamcinolone</claim-text>
<claim-text>xlvii. Olodaterol, tiotropium and flunisolide</claim-text>
<claim-text>xlviii. Olodaterol, tiotropium and dexomethasone</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0024" num="0024"><claim-text>The pharmaceutical composition according to any preceding claims, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinium, salmeterol and salbutamol</claim-text>
<claim-text>ii. Aclidinium, salmeterol and levosalbutamol</claim-text>
<claim-text>iii. Aclidinium, formoterol and salbutamol</claim-text>
<claim-text>iv. Aclidinium, formoterol and levosalbutamol</claim-text>
<claim-text>v. Aclidinium, arformoterol and salbutamol</claim-text>
<claim-text>vi. Aclidinium, arformoterol and levosalbutamol</claim-text>
<claim-text>vii. Aclidinium, indacaterol and salbutamol</claim-text>
<claim-text>viii. Aclidinium, indacaterol and levosalbutamol</claim-text>
<claim-text>ix. Aclidinium, olodaterol and salbutamol</claim-text>
<claim-text>x. Aclidinium, olodaterol and levosalbutamol</claim-text>
<claim-text>xi. Aclidinium, vilanterol and salbutamol</claim-text>
<claim-text>xii. Aclidinium, vilanterol and levosalbutamol</claim-text>
<claim-text>xiii. Aclidinium, carmoterol and salbutamol</claim-text>
<claim-text>xiv. Aclidinium, carmoterol and levosalbutamol</claim-text>
<claim-text>xv. Aclidinium, bambuterol and salbutamol</claim-text>
<claim-text>xvi. Aclidinium, bambuterol and levosalbutamol</claim-text>
<claim-text>xvii. Glycopyrronium, indacaterol and salbutamol</claim-text>
<claim-text>xviii. Glycopyrronium, indacaterol and levosalbutamol</claim-text>
<claim-text>xix. Glycopyrronium, salmeterol and salbutamol<!-- EPO <DP n="68"> --></claim-text>
<claim-text>xx. Glycopyrronium, salmeterol and levosalbutamol</claim-text>
<claim-text>xxi. Glycopyrronium, formoterol and salbutamol</claim-text>
<claim-text>xxii. Glycopyrronium, formoterol and levosalbutamol</claim-text>
<claim-text>xxiii. Glycopyrronium, arformoterol and salbutamol</claim-text>
<claim-text>xxiv. Glycopyrronium, arformoterol and levosalbutamol</claim-text>
<claim-text>xxv. Glycopyrronium, carmoterol and salbutamol</claim-text>
<claim-text>xxvi. Glycopyrronium, carmoterol and levosalbutamol</claim-text>
<claim-text>xxvii. Glycopyrronium, olodaterol and salbutamol</claim-text>
<claim-text>xxviii. Glycopyrronium, olodaterol and levosalbutamol</claim-text>
<claim-text>xxix. Glycopyrronium, vilanterol and salbutamol</claim-text>
<claim-text>xxx. Glycopyrronium, vilanterol and levosalbutamol</claim-text>
<claim-text>xxxi. Glycopyrronium, bambuterol and salbutamol</claim-text>
<claim-text>xxxii. Glycopyrronium, bambuterol and levosalbutamol</claim-text>
<claim-text>xxxiii. Daratropium, indacaterol and salbutamol</claim-text>
<claim-text>xxxiv. Daratropium, indacaterol and levosalbutamol</claim-text>
<claim-text>xxxv. Daratropium, salmeterol and salbutamol</claim-text>
<claim-text>xxxvi. Daratropium, salmeterol and levosalbutamol</claim-text>
<claim-text>xxxvii. Daratropium, formoterol and salbutamol</claim-text>
<claim-text>xxxviii. Daratropium, formoterol and levosalbutamol</claim-text>
<claim-text>xxxix. Daratropium, carmoterol and salbutamol</claim-text>
<claim-text>xl. Daratropium, carmoterol and levosalbutamol</claim-text>
<claim-text>xli. Daratropium, olodaterol and salbutamol</claim-text>
<claim-text>xlii. Daratropium, olodaterol and levosalbutamol</claim-text>
<claim-text>xliii. Daratropium, vilanterol and salbutamol</claim-text>
<claim-text>xliv. Daratropium, vilanterol and levosalbutamol</claim-text>
<claim-text>xlv. Daratropium, bambuterol and salbutamol</claim-text>
<claim-text>xlvi. Daratropium, bambuterol and levosalbutamol</claim-text>
<claim-text>xlvii. Daratropium, arformoterol and salbutamol</claim-text>
<claim-text>xlviii. Daratropium, arformoterol and levosalbutamol</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0025" num="0025"><claim-text>The pharmaceutical composition according to any preceding claims, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinium, salmeterol and mometasone<!-- EPO <DP n="69"> --></claim-text>
<claim-text>ii. Aclidinium, salmeterol and fluticasone</claim-text>
<claim-text>iii. Aclidinium, salmeterol and budesonide</claim-text>
<claim-text>iv. Aclidinium, formoterol and mometasone</claim-text>
<claim-text>v. Aclidinium, formoterol and fluticasone</claim-text>
<claim-text>vi. Aclidinium, formoterol and budesonide</claim-text>
<claim-text>vii. Aclidinium, arformoterol and mometasone</claim-text>
<claim-text>viii. Aclidinium, arformoterol and fluticasone</claim-text>
<claim-text>ix. Aclidinium, arformoterol and budesonide</claim-text>
<claim-text>x. Aclidinium, indacaterol and mometasone</claim-text>
<claim-text>xi. Aclidinium, indacaterol and fluticasone</claim-text>
<claim-text>xii. Aclidinium, indacaterol and budesonide</claim-text>
<claim-text>xiii. Aclidinium, olodaterol and mometasone</claim-text>
<claim-text>xiv. Aclidinium, olodaterol and fluticasone</claim-text>
<claim-text>xv. Aclidinium, olodaterol and budesonide</claim-text>
<claim-text>xvi. Aclidinium, vilanterol and mometasone</claim-text>
<claim-text>xvii. Aclidinium, vilanterol and fluticasone</claim-text>
<claim-text>xviii. Aclidinium, vilanterol and budesonide</claim-text>
<claim-text>xix. Aclidinium, carmoterol and mometasone</claim-text>
<claim-text>xx. Aclidinium, carmoterol and fluticasone</claim-text>
<claim-text>xxi. Aclidinium, carmoterol and budesonide</claim-text>
<claim-text>xxii. Aclidinium, bambuterol and mometasone</claim-text>
<claim-text>xxiii. Aclidinium, bambuterol and fluticasone</claim-text>
<claim-text>xxiv. Aclidinium, bambuterol and budesonide</claim-text>
<claim-text>xxv. Glycopyrronium, indacaterol and mometasone</claim-text>
<claim-text>xxvi. Glycopyrronium, indacaterol and fluticasone</claim-text>
<claim-text>xxvii. Glycopyrronium, indacaterol and budesonide</claim-text>
<claim-text>xxviii. Glycopyrronium, salmeterol and mometasone</claim-text>
<claim-text>xxix. Glycopyrronium, salmeterol and fluticasone</claim-text>
<claim-text>xxx. Glycopyrronium, salmeterol and budesonide</claim-text>
<claim-text>xxxi. Glycopyrronium, formoterol and mometasone</claim-text>
<claim-text>xxxii. Glycopyrronium, formoterol and fluticasone</claim-text>
<claim-text>xxxiii. Glycopyrronium, formoterol and budesonide</claim-text>
<claim-text>xxxiv. Glycopyrronium, arformoterol and mometasone</claim-text>
<claim-text>xxxv. Glycopyrronium, arformoterol and fluticasone</claim-text>
<claim-text>xxxvi. Glycopyrronium, arformoterol and budesonide</claim-text>
<claim-text>xxxvii. Glycopyrronium, carmoterol and mometasone</claim-text>
<claim-text>xxxviii. Glycopyrronium, carmoterol and fluticasone<!-- EPO <DP n="70"> --></claim-text>
<claim-text>xxxix. Glycopyrronium, carmoterol and budesonide</claim-text>
<claim-text>xl. Glycopyrronium, olodaterol and mometasone</claim-text>
<claim-text>xli. Glycopyrronium, olodaterol and fluticasone</claim-text>
<claim-text>xlii. Glycopyrronium, olodaterol and budesonide</claim-text>
<claim-text>xliii. Glycopyrronium, vilanterol and mometasone</claim-text>
<claim-text>xliv. Glycopyrronium, vilanterol and fluticasone</claim-text>
<claim-text>xlv. Glycopyrronium, vilanterol and budesonide</claim-text>
<claim-text>xlvi. Glycopyrronium, bambuterol and mometasone</claim-text>
<claim-text>xlvii. Glycopyrronium, bambuterol and fluticasone</claim-text>
<claim-text>xlviii. Glycopyrronium, bambuterol and budesonide</claim-text>
<claim-text>xlix. Daratropium, indacaterol and mometasone</claim-text>
<claim-text>l. Daratropium, indacaterol and fluticasone</claim-text>
<claim-text>li. Daratropium, indacaterol and budesonide</claim-text>
<claim-text>lii. Daratropium, salmeterol and mometasone</claim-text>
<claim-text>liii. Daratropium, salmeterol and fluticasone</claim-text>
<claim-text>liv. Daratropium, salmeterol and budesonide</claim-text>
<claim-text>lv. Daratropium, formoterol and mometasone</claim-text>
<claim-text>lvi. Daratropium, formoterol and fluticasone</claim-text>
<claim-text>lvii. Daratropium, formoterol and budesonide</claim-text>
<claim-text>lviii. Daratropium, carmoterol and mometasone</claim-text>
<claim-text>lix. Daratropium, carmoterol and fluticasone</claim-text>
<claim-text>lx. Daratropium, carmoterol and budesonide</claim-text>
<claim-text>lxi. Daratropium, olodaterol and mometasone</claim-text>
<claim-text>lxii. Daratropium, olodaterol and fluticasone</claim-text>
<claim-text>lxiii. Daratropium, olodaterol and budesonide</claim-text>
<claim-text>lxiv. Daratropium, vilanterol and mometasone</claim-text>
<claim-text>lxv. Daratropium, vilanterol and fluticasone</claim-text>
<claim-text>lxvi. Daratropium, vilanterol and budesonide</claim-text>
<claim-text>lxvii. Daratropium, bambuterol and mometasone</claim-text>
<claim-text>lxviii. Daratropium, bambuterol and fluticasone</claim-text>
<claim-text>lxix. Daratropium, bambuterol and budesonide</claim-text>
<claim-text>lxx. Daratropium, arformoterol and mometasone</claim-text>
<claim-text>lxxi. Daratropium, arformoterol and fluticasone</claim-text>
<claim-text>lxxii. Daratropium, arformoterol and budesonide</claim-text>
<claim-text>lxxiii. Indacaterol, salmeterol and mometasone</claim-text>
<claim-text>lxxiv. Indacaterol, salmeterol and fluticasone</claim-text>
<claim-text>lxxv. Indacaterol, salmeterol and budesonide<!-- EPO <DP n="71"> --></claim-text>
<claim-text>lxxvi. Indacaterol, formoterol and mometasone</claim-text>
<claim-text>lxxvii. Indacaterol, formoterol and fluticasone</claim-text>
<claim-text>lxxviii. Indacaterol, formoterol and budesonide</claim-text>
<claim-text>lxxix. Indacaterol, arformoterol and mometasone</claim-text>
<claim-text>lxxx. Indacaterol, arformoterol and fluticasone</claim-text>
<claim-text>lxxxi. Indacaterol, arformoterol and budesonide</claim-text>
<claim-text>lxxxii. Indacaterol, olodaterol and mometasone</claim-text>
<claim-text>lxxxiii. Indacaterol, olodaterol and fluticasone</claim-text>
<claim-text>lxxxiv. Indacaterol, olodaterol and budesonide</claim-text>
<claim-text>lxxxv. Indacaterol, vilanterol and mometasone</claim-text>
<claim-text>lxxxvi. Indacaterol, vilanterol and fluticasone</claim-text>
<claim-text>lxxxvii. Indacaterol, vilanterol and budesonide</claim-text>
<claim-text>lxxxviii. Indacaterol, carmeterol and mometasone</claim-text>
<claim-text>lxxxix. Indacaterol, carmeterol and fluticasone</claim-text>
<claim-text>xc. Indacaterol, carmeterol and budesonide</claim-text>
<claim-text>xci. Indacaterol, bambuterol and mometasone</claim-text>
<claim-text>xcii. Indacaterol, bambuterol and fluticasone</claim-text>
<claim-text>xciii. Indacaterol, bambuterol and budesonide</claim-text>
<claim-text>xciv. Vilanterol, salmeterol and mometasone</claim-text>
<claim-text>xcv. Vilanterol, salmeterol and fluticasone</claim-text>
<claim-text>xcvi. Vilanterol, salmeterol and budesonide</claim-text>
<claim-text>xcvii. Vilanterol, formoterol and mometasone</claim-text>
<claim-text>xcviii. Vilanterol, formoterol and fluticasone</claim-text>
<claim-text>xcix. Vilanterol, formoterol and budesonide</claim-text>
<claim-text>c. Vilanterol, arformoterol and mometasone</claim-text>
<claim-text>ci. Vilanterol, arformoterol and fluticasone</claim-text>
<claim-text>cii. Vilanterol, arformoterol and budesonide</claim-text>
<claim-text>ciii. Vilanterol, olodaterol and mometasone</claim-text>
<claim-text>civ. Vilanterol, olodaterol and fluticasone</claim-text>
<claim-text>cv. Vilanterol, olodaterol and budesonide</claim-text>
<claim-text>cvi. Vilanterol, carmeterol and mometasone</claim-text>
<claim-text>cvii. Vilanterol, carmeterol and fluticasone</claim-text>
<claim-text>cviii. Vilanterol, carmeterol and budesonide</claim-text>
<claim-text>cix. Vilanterol, bambuterol and mometasone</claim-text>
<claim-text>cx. Vilanterol, bambuterol and fluticasone</claim-text>
<claim-text>cxi. Vilanterol, bambuterol and budesonide</claim-text>
<claim-text>cxii. Vilanterol, indacaterol and mometasone<!-- EPO <DP n="72"> --></claim-text>
<claim-text>cxiii. Vilanterol, indacaterol and fluticasone</claim-text>
<claim-text>cxiv. Vilanterol, indacaterol and budesonide</claim-text>
<claim-text>cxv. Carmeterol, salmeterol and mometasone</claim-text>
<claim-text>cxvi. Carmeterol, salmeterol and fluticasone</claim-text>
<claim-text>cxvii. Carmeterol, salmeterol and budesonide</claim-text>
<claim-text>cxviii. Carmeterol, formoterol and mometasone</claim-text>
<claim-text>cxix. Carmeterol, formoterol and fluticasone</claim-text>
<claim-text>cxx. Carmeterol, formoterol and budesonide</claim-text>
<claim-text>cxxi. Carmeterol, arformoterol and mometasone</claim-text>
<claim-text>cxxii. Carmeterol, arformoterol and fluticasone</claim-text>
<claim-text>cxxiii. Carmeterol, arformoterol and budesonide</claim-text>
<claim-text>cxxiv. Carmeterol, indaceterol and mometasone</claim-text>
<claim-text>cxxv. Carmeterol, indaceterol and fluticasone</claim-text>
<claim-text>cxxvi. Carmeterol, indaceterol and budesonide</claim-text>
<claim-text>cxxvii. Carmeterol, olodaterol and mometasone</claim-text>
<claim-text>cxxviii. Carmeterol, olodaterol and fluticasone</claim-text>
<claim-text>cxxix. Carmeterol, olodaterol and budesonide</claim-text>
<claim-text>cxxx. Carmeterol, vilanterol and mometasone</claim-text>
<claim-text>cxxxi. Carmeterol, vilanterol and fluticasone</claim-text>
<claim-text>cxxxii. Carmeterol, vilanterol and budesonide</claim-text>
<claim-text>cxxxiii. Carmeterol, bambuterol and mometasone</claim-text>
<claim-text>cxxxiv. Carmeterol, bambuterol and fluticasone</claim-text>
<claim-text>cxxxv. Carmeterol, bambuterol and budesonide</claim-text>
<claim-text>cxxxvi. Olodaterol, salmeterol and mometasone</claim-text>
<claim-text>cxxxvii. Olodaterol, salmeterol and fluticasone</claim-text>
<claim-text>cxxxviii. Olodaterol, salmeterol and budesonide</claim-text>
<claim-text>cxxxix. Olodaterol, formoterol and mometasone</claim-text>
<claim-text>cxl. Olodaterol, formoterol and fluticasone</claim-text>
<claim-text>cxli. Olodaterol, formoterol and budesonide</claim-text>
<claim-text>cxlii. Olodaterol, arformoterol and mometasone</claim-text>
<claim-text>cxliii. Olodaterol, arformoterol and fluticasone</claim-text>
<claim-text>cxliv. Olodaterol, arformoterol and budesonide</claim-text>
<claim-text>cxlv. Olodaterol, indacaterol and mometasone</claim-text>
<claim-text>cxlvi. Olodaterol, indacaterol and fluticasone</claim-text>
<claim-text>cxlvii. Olodaterol, indacaterol and budesonide</claim-text>
<claim-text>cxlviii. Olodaterol, vilanterol and mometasone</claim-text>
<claim-text>cxlix. Olodaterol, vilanterol and fluticasone<!-- EPO <DP n="73"> --> cl. Olodaterol, vilanterol and budesonide</claim-text>
<claim-text>cli. Olodaterol, carmeterol and mometasone</claim-text>
<claim-text>clii. Olodaterol, carmeterol and fluticasone</claim-text>
<claim-text>cliii. Olodaterol, carmeterol and budesonide</claim-text>
<claim-text>cliv. Olodaterol, bambuterol and mometasone</claim-text>
<claim-text>clv. Olodaterol, bambuterol and fluticasone</claim-text>
<claim-text>clvi. Olodaterol, bambuterol and budesonide</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0026" num="0026"><claim-text>The pharmaceutical composition according to any preceding claims, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Aclidinium, salbutamol and fluticasone</claim-text>
<claim-text>ii. Aclidinium, levosalbutamol and fluticasone</claim-text>
<claim-text>iii. Aclidinium, salbutamol and ciclesonide</claim-text>
<claim-text>iv. Aclidinium, levosalbutamol and ciclesonide</claim-text>
<claim-text>v. Aclidinium, salbutamol and budesonide</claim-text>
<claim-text>vi. Aclidinium, levosalbutamol and budesonide</claim-text>
<claim-text>vii. Aclidinium, salbutamol and mometasone</claim-text>
<claim-text>viii. Aclidinium, levosalbutamol and mometasone</claim-text>
<claim-text>ix. Aclidinium, salbutamol and beclometahsone</claim-text>
<claim-text>x. Aclidinium, levosalbutamol and beclometahsone</claim-text>
<claim-text>xi. Aclidinium, salbutamol and triamcinolone</claim-text>
<claim-text>xii. Aclidinium, levosalbutamol and triamcinolone</claim-text>
<claim-text>xiii. Aclidinium, salbutamol and flunisolide</claim-text>
<claim-text>xiv. Aclidinium, levosalbutamol and flunisolide</claim-text>
<claim-text>xv. Aclidinium, salbutamol and dexamethasone</claim-text>
<claim-text>xvi. Aclidinium, levosalbutamol and dexamethasone</claim-text>
<claim-text>xvii. Glycopyrronium, salbutamol and fluticasone</claim-text>
<claim-text>xviii. Glycopyrronium, levosalbutamol and fluticasone</claim-text>
<claim-text>xix. Glycopyrronium, salbutamol and ciclesonide</claim-text>
<claim-text>xx. Glycopyrronium, levosalbutamol and ciclesonide</claim-text>
<claim-text>xxi. Glycopyrronium, salbutamol and budesonide</claim-text>
<claim-text>xxii. Glycopyrronium, levosalbutamol and budesonide</claim-text>
<claim-text>xxiii. Glycopyrronium, salbutamol and mometasone<!-- EPO <DP n="74"> --></claim-text>
<claim-text>xxiv. Glycopyrronium, levosalbutamol and mometasone</claim-text>
<claim-text>xxv. Glycopyrronium, salbutamol and beclometahsone</claim-text>
<claim-text>xxvi. Glycopyrronium, levosalbutamol and beclometahsone</claim-text>
<claim-text>xxvii. Glycopyrronium, salbutamol and triamcinolone</claim-text>
<claim-text>xxviii. Glycopyrronium, levosalbutamol and triamcinolone</claim-text>
<claim-text>xxix. Glycopyrronium, salbutamol and flunisolide</claim-text>
<claim-text>xxx. Glycopyrronium, levosalbutamol and flunisolide</claim-text>
<claim-text>xxxi. Glycopyrronium, salbutamol and dexamethasone</claim-text>
<claim-text>xxxii. Glycopyrronium, levosalbutamol and dexamethasone</claim-text>
<claim-text>xxxiii. Daratropium, salbutamol and fluticasone</claim-text>
<claim-text>xxxiv. Daratropium, levosalbutamol and fluticasone</claim-text>
<claim-text>xxxv. Daratropium, salbutamol and ciclesonide</claim-text>
<claim-text>xxxvi. Daratropium, levosalbutamol and ciclesonide</claim-text>
<claim-text>xxxvii. Daratropium, salbutamol and budesonide</claim-text>
<claim-text>xxxviii. Daratropium, levosalbutamol and budesonide</claim-text>
<claim-text>xxxix. Daratropium, salbutamol and mometasone</claim-text>
<claim-text>xl. Daratropium, levosalbutamol and mometasone</claim-text>
<claim-text>xli. Daratropium, salbutamol and beclometahsone</claim-text>
<claim-text>xlii. Daratropium, levosalbutamol and beclometahsone</claim-text>
<claim-text>xliii. Daratropium, salbutamol and triamcinolone</claim-text>
<claim-text>xliv. Daratropium, levosalbutamol and triamcinolone</claim-text>
<claim-text>xlv. Daratropium, salbutamol and flunisolide</claim-text>
<claim-text>xlvi. Daratropium, levosalbutamol and flunisolide</claim-text>
<claim-text>xlvii. Daratropium, salbutamol and dexamethasone</claim-text>
<claim-text>xlviii. Daratropium, levosalbutamol and dexamethasone</claim-text>
<claim-text>xlix. Indacaterol, salbutamol and fluticasone</claim-text>
<claim-text>l. Indacaterol, levosalbutamol and fluticasone</claim-text>
<claim-text>li. Indacaterol, salbutamol and ciclesonide</claim-text>
<claim-text>lii. Indacaterol, levosalbutamol and ciclesonide</claim-text>
<claim-text>liii. Indacaterol, salbutamol and budesonide</claim-text>
<claim-text>liv. Indacaterol, levosalbutamol and budesonide</claim-text>
<claim-text>lv. Indacaterol, salbutamol and mometasone</claim-text>
<claim-text>lvi. Indacaterol, levosalbutamol and mometasone</claim-text>
<claim-text>lvii. Indacaterol, salbutamol and beclometahsone</claim-text>
<claim-text>lviii. Indacaterol, levosalbutamol and beclometahsone</claim-text>
<claim-text>lix. Indacaterol, salbutamol and triamcinolone</claim-text>
<claim-text>lx. Indacaterol, levosalbutamol and triamcinolone<!-- EPO <DP n="75"> --></claim-text>
<claim-text>lxi. Indacaterol, salbutamol and flunisolide</claim-text>
<claim-text>lxii. Indacaterol, levosalbutamol and flunisolide</claim-text>
<claim-text>lxiii. Indacaterol, salbutamol and dexamethasone</claim-text>
<claim-text>lxiv. Indacaterol, levosalbutamol and dexamethasone</claim-text>
<claim-text>lxv. Vilanterol, salbutamol and fluticasone</claim-text>
<claim-text>lxvi. Vilanterol, levosalbutamol and fluticasone</claim-text>
<claim-text>lxvii. Vilanterol, salbutamol and budesonide</claim-text>
<claim-text>lxviii. Vilanterol, levosalbutamol and budesonide</claim-text>
<claim-text>lxix. Vilanterol, salbutamol and ciclesonide</claim-text>
<claim-text>lxx. Vilanterol, levosalbutamol and ciclesonide</claim-text>
<claim-text>lxxi. Vilanterol, salbutamol and mometasone</claim-text>
<claim-text>lxxii. Vilanterol, levosalbutamol and mometasone</claim-text>
<claim-text>lxxiii. Vilanterol, salbutamol and beclomethasone</claim-text>
<claim-text>lxxiv. Vilanterol, levosalbutamol and beclomethasone</claim-text>
<claim-text>lxxv. Vilanterol, salbutamol and triamcinolone</claim-text>
<claim-text>lxxvi. Vilanterol, levosalbutamol and triamcinolone</claim-text>
<claim-text>lxxvii. Vilanterol, salbutamol and flunisolide</claim-text>
<claim-text>lxxviii. Vilanterol, levosalbutamol and flunisolide</claim-text>
<claim-text>lxxix. Vilanterol, salbutamol and dexamethasone</claim-text>
<claim-text>lxxx. Vilanterol, levosalbutamol and dexamethasone</claim-text>
<claim-text>lxxxi. Carmeterol, salbutamol and fluticasone</claim-text>
<claim-text>lxxxii. Carmeterol, levosalbutamol and fluticasone</claim-text>
<claim-text>lxxxiii. Carmeterol, salbutamol and ciclesonide</claim-text>
<claim-text>lxxxiv. Carmeterol, levosalbutamol and ciclesonide</claim-text>
<claim-text>lxxxv. Carmeterol, salbutamol and budesonide</claim-text>
<claim-text>lxxxvi. Carmeterol, levosalbutamol and budesonide</claim-text>
<claim-text>lxxxvii. Carmeterol, salbutamol and mometasone</claim-text>
<claim-text>lxxxviii. Carmeterol, levosalbutamol and mometasone</claim-text>
<claim-text>lxxxix. Carmeterol, salbutamol and beclomethasone</claim-text>
<claim-text>xc. Carmeterol, levosalbutamol and beclomethasone</claim-text>
<claim-text>xci. Carmeterol, salbutamol and triamcinolone</claim-text>
<claim-text>xcii. Carmeterol, levosalbutamol and triamcinolone</claim-text>
<claim-text>xciii. Carmeterol, salbutamol and flunisolide</claim-text>
<claim-text>xciv. Carmeterol, levosalbutamol and flunisolide</claim-text>
<claim-text>xcv. Carmeterol, salbutamol and dexamethasone</claim-text>
<claim-text>xcvi. Carmeterol, levosalbutamol and dexamethasone</claim-text>
<claim-text>xcvii. Olodaterol, salbutamol and fluticasone<!-- EPO <DP n="76"> --></claim-text>
<claim-text>xcviii. Olodaterol, levosalbutamol and fluticasone</claim-text>
<claim-text>xcix. Olodaterol, salbutamol and ciclesonide</claim-text>
<claim-text>c. Olodaterol, levosalbutamol and ciclesonide</claim-text>
<claim-text>ci. Olodaterol, salbutamol and budesonide</claim-text>
<claim-text>cii. Olodaterol, levosalbutamol and budesonide</claim-text>
<claim-text>ciii. Olodaterol, salbutamol and mometasone</claim-text>
<claim-text>civ. Olodaterol, levosalbutamol and mometasone</claim-text>
<claim-text>cv. Olodaterol, salbutamol and beclomethasone</claim-text>
<claim-text>cvi. Olodaterol, levosalbutamol and beclomethasone</claim-text>
<claim-text>cvii. Olodaterol, salbutamol and triamcinolone</claim-text>
<claim-text>cviii. Olodaterol, levosalbutamol and triamcinolone</claim-text>
<claim-text>cix. Olodaterol, salbutamol and flunisolide</claim-text>
<claim-text>cx. Olodaterol, levosalbutamol and flunisolide</claim-text>
<claim-text>cxi. Olodaterol, salbutamol and dexamethasone</claim-text>
<claim-text>cxii. Olodaterol, levosalbutamol and dexamethasone</claim-text>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim><claim id="c-en-0027" num="0027"><claim-text>The pharmaceutical composition according to any preceding claims, comprising any of the following combinations, said combinations being suitable for administration separately, sequentially or together in effective amounts;
<claim-text>i. Formoterol, budesonide and tiotropium</claim-text>
<claim-text>ii. Salmeterol, fluticasone and tiotropium</claim-text>
<claim-text>iii. Carmoterol, tiotropium and fluticasone</claim-text>
<claim-text>iv. Salbutamol, formoterol and budesonide</claim-text>
<claim-text>v. Salbutamol, salmeterol and fluticasone</claim-text>
<claim-text>vi. Salbutamol, arformoterol and fluticasone<br/>
wherein the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.</claim-text></claim-text></claim><claim id="c-en-0028" num="0028"><claim-text>The pharmaceutical composition according to any of the preceding claims, wherein the therapeutically effective amount of said pharmaceutical composition is administered once a day or said pharmaceutical composition is administered twice a day.<!-- EPO <DP n="77"> --></claim-text></claim><claim id="c-en-0029" num="0029"><claim-text>The pharmaceutical composition according to any of the preceding claims, for use in the treatment of respiratory condition selected from asthma and chronic obstructive pulmonary disease and other obstructive airways diseases.</claim-text></claim><claim id="c-en-0030" num="0030"><claim-text>The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition being suitable for administarion separately, sequentially or together in effective amounts, together with a moisture tight and high barrier sealed blister.</claim-text></claim><claim id="c-en-0031" num="0031"><claim-text>The pharmaceutical composition according to any of the preceding claims, wherein said pharmaceutical composition being suitable for administarion separately, sequentially or together in effective amounts, together with a capsule.</claim-text></claim><claim id="c-en-0032" num="0032"><claim-text>The pharmaceutical composition according to claim 30 or 31, wherein said pharmaceutical composition being suitable for administration separately, sequentially or together in effective amounts, together with a dry powder inhalation device.</claim-text></claim><claim id="c-en-0033" num="0033"><claim-text>The pharmaceutical composition according to claim 30, wherein said pharmaceutical composition being suitable for administration separately, sequentially or together in effective amounts, together with an inhalation device <b>characterized by</b> said device comprise at least one lock mechanism, enabling the device to remain locked in both positions in which the device is ready for inhalation and the lid is in the closed position, and further enabling the device to setup again automatically, when the lid is closed.</claim-text></claim><claim id="c-en-0034" num="0034"><claim-text>A pharmaceutical kit comprising the drugs having amine as defined in claim 1 and one or more additional active agents as defined in claim 12, in separate unit dosage forms, said forms being suitable for administration separately, sequentially or together in effective amounts, together with one or more inhalation devices for administration of drugs having amine and one or more additional active agents.</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
